AU2007207089A1 - Test systems for the analysis of polypeptides and cells adhering to silicones - Google Patents

Test systems for the analysis of polypeptides and cells adhering to silicones Download PDF

Info

Publication number
AU2007207089A1
AU2007207089A1 AU2007207089A AU2007207089A AU2007207089A1 AU 2007207089 A1 AU2007207089 A1 AU 2007207089A1 AU 2007207089 A AU2007207089 A AU 2007207089A AU 2007207089 A AU2007207089 A AU 2007207089A AU 2007207089 A1 AU2007207089 A1 AU 2007207089A1
Authority
AU
Australia
Prior art keywords
silicone
polypeptide
adhering
protein
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007207089A
Inventor
Aleksander Backovic
Georg Wick
Nikolaus Wick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wick Immunologische Diagnostik und Beratung KG
Original Assignee
Wick Immunologische Diagnostik und Beratung KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06001053A external-priority patent/EP1811297A1/en
Application filed by Wick Immunologische Diagnostik und Beratung KG filed Critical Wick Immunologische Diagnostik und Beratung KG
Publication of AU2007207089A1 publication Critical patent/AU2007207089A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

WO 2007/082757 PCT/EP2007/000442 Test Systems for the Analysis of Polypeptides and Cells Adhering to Silicones 5 The present invention relates in general to the field of diagnostics, namely to test systems for polypeptides in respect to silicone. More precisely, the present invention, in one embodiment thereof, concerns test systems for identifying and analyzing polypeptides adhering to silicone. Furthermore, the present invention relates to newly identified polypeptides adhering to 10 silicone and to respective uses of such proteins, e.g., in test systems for detecting a response reaction of a mammal to a silicone. BACKGROUND OF THE INVENTION 15 Dimethylsiloxane polymer, also known as 'silicone', is the most widely utilized inorganic biomaterial in medical practice, because of its assumed biocompatibility. It is used in a large variety of applications, such as medical tubing systems, syringe lubricants, coating of active medical devices like bypass apparatus and cochlear implants, and for the production of passive implants ranging from joint replacements and eye lenses to ventriculo-peritoneal 20 shunts, and mammary implants. However, particularly after long-term implantation, various local and systemic side effects have been reported as a response reaction to silicone. These phenomena have been observed, for example, in women with silicone mammary implants (SMIs) [Smalley, D. L., Levine, J. J., 25 Shanklin, D. R., Hall, M. F., and Stevens, M. V. Lymphocyte response to silica among offspring of silicone breast implant recipients. Immunobiology 196, 567-574 (1996)], in most cases of failures of sterile ventriculo-peritoneal shunts [Goldblum, R. M., Pelley, R. P., O'Donell, A. A., Pyron, D., and Heggers, J. P. Antibodies to silicone elastomers and reactions to ventriculoperitoneal shunts. Lancet 340, 510-513 (1992)], and also in patients carrying 30 various silicone coated medical devices [Kinnari, T. J., Salonen, E. M., and Jero, J. Durability of the binding inhibition of albumin coating on tympanostomy tubes. International Journal of Pediatric Otorhinolaryngology 67, 157-164 (2003)]. The so-called local reaction of the organism against the silicone is characterized by the 35 formation of a fibrotic connective tissue capsule that can vary in extent [Siggelkow, W., WO 2007/082757 PCT/EP2007/000442 -2 Faridi, A., Spiritus, K., Klinge, U., Rath, W., and Klosterhalfen, B. Histological analysis of silicone breast implant capsules and correlation with capsular contracture. Biomaterials 24, 1101-1109 (2003)]. Over the course of years, the fibrosis progresses causing functional impairment of the implant. Local side effects are often followed by systemic problems, and 5 there have been reports on patients with long term silicone implants that have been diagnosed with fibromyalgia [Vermeulen, R. C. and Scholte, H. R. Rupture of silicone gel breast implants and symptoms of pain and fatigue. The Journal of Rheumatology 30, 2263-2267 (2003); Shanklin, D. R., Stevens, M. V., Hall, M. F., and Smalley, D. L. Environmental immunogens and T-cell-mediated responses in fibromyalgia: evidence for immune 10 dysregulation and determinants of granuloma formation. Experimental and Molecular Pathology 69, 102-118 (2000)], rheumatic and other types of connective tissue disease (CTD) [Bridges, A. J., Conley, C., Wang, G., Bums, D. E., and Vasey, F. B. A clinical and immunologic evaluation of women with silicone breast implants and symptoms of rheumatic disease. Ann Intern Med 118, 929-936 (1993)], and even with a scleroderma-like fibrotic 15 syndrome [Varga, J., Schumacher, H. R., and Jimenez, S. A. Systemic sclerosis after augmentation mammoplasty with silicone implants. Cancer Research 111, 377-383 (1989); Appleton, B. E. and Lee, P. The development of systemic sclerosis (scleroderma) following augmentation mammoplasty. JRheumatol 20, 1052-1054 (1998)]. 20 Although it is generally believed that the systemic side effects reflect changes on the local level, such a crosstalk has never been defined. Even more important, prospective cohort studies, both in Europe and the United States, could neither confirm nor deny the effect of silicone implants as a risk factor for the development of CTD or other autoimmune diseases [Janowsky, E. C., Kupper, L. L., and Hulka, B. S. Meta-analyses of the relation between 25 silicone breast implants and the risk of connective-tissue diseases. New England Journal of Medicine 342, 781-790 (2000); Sanchez-Guerrero, J., Colditz, G. A., Karlson, E. W., Hunter, D. J., Speizer, F. E., and Liang, M. H. Silicone Breast Implants and the Risk of Connective Tissue Diseases and Symptoms. N Engl JMed 332, 1666-1670 (1995)]. 30 Nevertheless, it has been shown that connective tissue disease-like symptoms in carriers of SMIs disappeared after the removal of the implant [Zazgornik, J., Piza, H., Kaiser, W., Bettelheim, P., Steiner, G., Smolen, J., Biesenbach, G., and Maschek, W. Autoimmune reactions in patients with silicone breast implants. Wien. Klin. Wochenschr. 108, 781-787 (1996)]. Furthermore, it could be shown that there was a contribution of the immunological WO 2007/082757 PCT/EP2007/000442 -3 mechanism to the development of peri-SMI capsule formation [Wolfram, D., Rainer, C., Niederegger, H., Piza, H., and Wick, G. Cellular and molecular composition of fibrous capsules formed around silicone breast implants with special focus on local immune reactions. J Autoimmun. 23, 81-91 (2004)]. In the latter report it was demonstrated that within these 5 capsules delayed type hypersensitivity reactions take place. Most experts agree that the reaction to silicone is a type of low intensity perpetuated foreign body reaction, but the mechanisms behind those processes are not exactly known. Even though activation of immune response to silicone has been demonstrated, it is not clear, 10 whether (i) silicone itself has antigenic properties, (ii) acts as a hapten or carrier, (iii) represents an immunological adjuvant, (iv) is a surface that promotes exposure of cryptic antigens and 'altered self, or (v) induces a stress response in the surrounding tissue. Even though it has been identified as a key factor in an immune reaction to silicone, the 15 composition of the proteinaceous film on the surface of silicone is poorly understood. It is acquired on the implanted silicone surface almost instantaneously after the implantation [Elwing, H. Protein absorption and ellipsometry in biomaterial research. Biomaterials 19, 397-406 (1998)]. Proteins forming the film are recognized by phagocytes and fibroblasts that are the first cells interacting with the implant. 20 It is important to emphasize that in biological systems, flow conditions, protein conformational changes, competitive adsorption of proteins, and early effects in blood clotting and complement activation strongly influence the formation of the protein film on the artificial surfaces ('Vroman effect') [Vroman, L., Adams, A.L., Fischer, G.C., and Munoz, 25 P.C. Interaction of High Molecular-Weight Kininogen, Factor-Xii, and Fibrinogen in Plasma at Interfaces. Blood 55, 156-159 (1980)]. Because of the complexity of the film, it has so far been only shown that the y190-202 cryptic immunogenic epitope of the fibrinogen D domain is able to activate macrophages [through MAC-I (CD1 lb/CD 18) on their surface] [Hu, W.J., Eaton, J.W., Ugarova, T.P., and Tang, L. Molecular basis of biomaterial-mediated foreign 30 body reactions. Blood 98, 1231-1238 (2001)]. This epitope of fibrinogen is exposed only upon adhesion to a silicone surface and plays a crucial role in local side effects of SMIs. As a response, activated macrophages produce TNF-a, leading to the recruitment of lymphocytes and inducing transdifferentiation, proliferation and migration of fibroblasts to the surrounding tissue. Fibrosis occurs as the response of the surrounding tissue to the chronic inflammatory WO 2007/082757 PCT/EP2007/000442 -4 reaction to silicone, constantly perpetuated by lymphocyte, fibroblasts and macrophages interacting with proteins adhered to silicone surface. More evidence for the immune hypothesis of the fibrotic capsule formation can be found in 5 the composition of the peri-implant connective tissue capsule. Capsule formation has been investigated on an immunohistological level in numerous studies with similar findings [Wick, G., Wagner, R., Klima, G., and Wilflingseder, P. in Cellular, Molecular and Genetic Approaches to Immunodiagnosis and Immunotherapy. eds. Kano, K., Mori, S., Sugisaki, T., and Torisu, M. 231-241 (University of Tokyo Press, Tokyo; 1987) and Gabbiani, G., 10 Hirschel, B.J., Ryan, G.B., Statkov, P. R., and Majno, G. Granulation tissue as a contractile organ. A study of structure and function. The Journal of Experimental Medicine 135, 719-734 (1972)]. It has been shown that a synovial-like multilayer metaplasia composed of cells with 15 macrophage and fibroblastic phenotype is formed towards the implant. Interestingly, these cells also express abundant amount of stress proteins, like Heat Shock Protein 60 (HSP60), on the surface of SMIs [Wolfram, D., Rainer, C., Niederegger, H., Piza, H., and Wick, G. Cellular and molecular composition of fibrous capsules formed around silicone breast implants with special focus on local immune reactions. J Autoimmun. 23, 81-91 (2004)]. The 20 chronic proliferative inflammation pattern of fibroblasts is resulting in dense collagenous fibrosis after an implant duration of more than two years [Siggelkow, W., Faridi, A., Klinge, U., Rath, W., and Klosterhalfen, B. Ki67, HSP70 and TUNEL for the specification of testing of silicone breast implants in vivo. J Mater. Sci. Mater. Med 15, 1355-1360 (2004)]. Additional stimulation of local fibrotic processes through secretion of Connective Tissue 25 Growth Factor (CTGF) is mediated by y6-T-cells in the capsule [Workalemahu, G., Foerster, M., Kroegel, C., and Braun, R. K. Human gamma delta-T lymphocytes express and synthesize connective tissue growth factor: effect of IL- 15 and TGF-beta 1 and comparison with alpha beta-T lymphocytes. The Journal of Biological Chemistry 170, 153-157 (2003)], which was also found in the peri-implant connective tissue capsule. In addition, macrophages 30 are stimulated via a positive feedback loop by TNF-a produced by yS-T-cells. The evaluation of the host response to implanted materials requires systematic, objective investigations of responses at both the cellular and molecular levels. Hunt et al. [Hunt, J.A., McLaughlin, P.J. and Flanagan, B.F. Techniques to investigate cellular and molecular WO 2007/082757 PCT/EP2007/000442 -5 interactions in the host response to implanted biomaterials. Biomaterials 18(22), 1449-1459 (1997)] describe current technologies for the development of antibodies as tools to study cell markers or molecules, including those for which reagents are not yet available, and DNA based technologies, whose continued application should prove an invaluable adjunct to 5 existing approaches. US 4,048,298 discloses a solid double-antibody radioimmunoassay procedure. The patent concerns a radioimmunoassay (RIA) procedure for assaying body fluid content of an antigenic substance which may either be an antigen itself or a hapten capable of being 10 converted, such as by means of reaction with a protein, to an antigenic material. This invention relates to a novel and improved modification of a double-antibody RIA technique in which there is a first antibody that is specific to the antigenic substance suspected to be present in a body fluid from which the assay is intended. The second antibody, however, is not specific to the antigenic substance or analyte, but is an antibody against the first antibody. 15 WO 02/41000 discloses an immunoassay method for membrane-bound matrix metalloprotease. By using a simple procedure and a reagent, MT1-MMP can be quickly quantified or the enzymatic activity of MT1 -MMP can be measured at a high sensitivity and a high accuracy. Namely, use of a method of immunologically quantifying MT 1 -MMP by using 20 an anti-MT1-MMP antibody and a reagent to be used therewith; a method of immunologically quantifying a member selected from the group consisting of (i) MT1-MMP having been released and/or solubilized from cell membrane with the use of a surfactant and/or a reducing agent and (ii) autonomously solubilized MT1-MMP and a reagent to be used therewith; and solid-phase MTl-MMP makes it possible to quantify MT1-MMP or measure the enzymatic 25 activity of MT1-MMP. Moreover, an MT1-MMP expression promoter or inhibitor and an MT1-MMP activity promoter or inhibitor can be screened thereby. Thus, research and development of useful drugs can be facilitated. These reagents are also useful in examining cancer and cancer metastasis. 30 US 5,389,518 describes monoclonal antibodies directed against specific domains of fibronectin and vitronectin that can be deposited on a polymer, for example on silicone. These antibodies are able to bind to the proteins fibronctin and vitronectin, which in turn can serve as biological substrates. However, the direct binding of fibronectin and vitronectin to a silicone surface is not shown.
WO 2007/082757 PCT/EP2007/000442 -6 Silicone breast implants have a controversial history and are no longer approved for use by the Food and Drug Administration. They consisted of a flexible silicone rubber outer envelope that was filled with a silicone gel. Anecdotal reports of complications related to 5 silicone breast implants are numerous including associations with connective tissue disorders such as scleroderma and rheumatoid syndromes. Indisputable complications of all types of breast implants include surgically related complications such as bleeding and infection. Later in the life of an implant, the predominant 10 complications include capsular contracture and implant rupture. However, there are analogous complications against the outer envelope of an intact silicone implant. The cause of these complications remains elusive although some interesting things have been demonstrated. For instance, the gel inside the silicone implant is in a polymerized form. 15 Unpolymerized silicone can bleed through an intact silicone envelope into the surrounding tissue. It is theorized that this unpolymerized silicone stimulates the fibrotic reaction responsible for capsular contraction. Silicone bleeding through an intact envelope, as well as implant rupture, is associated with granuloma formation. Nevertheless, also polymerised silicone that covers the surface of an intact implant, i.e. the "true" surface, has a potential for a 20 granulomatous or fibrotic capsule formation, i.e. even without bleeding of the silicone. Currently, the interaction between proteins and silicone is only little understood. It has been shown that the special silicone, octamethylcyclotetrasiloxane (D 4 ) induces denaturation and conformational changes in fibrinogen and fibronectin, however, there is no evidence for their 25 relevance in immunogenicity [Sun, L., Alexander, H., Lattarulo, N., Blumenthal, N. C., Ricci, J. L., and Chen, G. Protein denaturation induced by cyclic silicone. Biomaterials 18, 1593 1597 (1997)]. Tavazzani et al. developed a model of human monocyte-derived macrophages to address the 30 mechanisms of silicone-induced inflammation. With this model it was shown that the interaction between collagen type I and a silicone gel induces IL-1 secretion by the cells. However, the binding characteristics of collagen to silicone was not investigated [Tavazzani, F., Xing, S., Waddell, J. E., Smith, D., and Boynton, E.L. In vitro interaction between silicone WO 2007/082757 PCT/EP2007/000442 -7 gel and human monocyte-macrophages. J Biomed Mat. Res. - Part A, 72, 2, 161-167 (2004)]. In another study, Wolfram et al. [Wolfram, D., Rainer, C., Niederegger, H., Piza, H., and 5 Wick, G. Cellular and molecular composition of fibrous capsules formed around silicone breast implants with special focus on local immune reactions. JAutoimmun. 23, 81-91 (2004)] showed that silicone induces a stringent local T-cell immune response and that there are several proteins located in an implant capsule. These proteins include (a) the collagenous proteins (pro)collagen types I and III, collagen type IV, (b) the non-collagenous proteins 10 tenascin, fibronectin and laminin, and (c) heat shock protein 60. However, there are no data provided showing the binding of these proteins to silicone. Instead, the capsule distant from the silicone surface was investigated. The authors only speculate on eventual functions of the proteins as immunogens, for example, after the exposure of a previously cryptic epitope. 15 Backovic et al. investigated the immunological basis of a peri-implant capsule formation [A., Oberreiter, B., Del Frari, B., Huang, H.L., Piza, H., Wick, G. Joint Annual Meeting of the German and Scandinavian Societies of Immunology, 21-24 September 2005, Kiel, Germany. Immunobiology 210, no. 6-8, 2005]. In this study, a proteinacious film covering the SI in vivo was analyzed and a protein set of 183 spots was identified out of which three proteins were 20 mentioned, namely, fibronectin, vitronectin and heat shock protein 60. There are no further details given. Despite the above progresses, there still is a need in the prior art to provide methods and devices in order to further explore the role of silicone-adhering proteins and the proteinaceous 25 film, and in particular the interaction of cells and extracellular matrix (ECM) proteins with silicone, and to identify novel proteins that are able to adhere to silicone surfaces. A better understanding of the mechanisms underlying the reaction of a subject to silicone is essential, for example, if one aims at identifying individuals prone to develop local or systemic side effects as described above and to base appropriate methods for monitoring, prevention and 30 therapy on these results. In addition, a better understanding also plays a crucial role for providing silicone having a higher biocompatibility. SUMMARY OF THE INVENTION WO 2007/082757 PCT/EP2007/000442 -8 In a first aspect thereof, the present invention provides a method for identifying polypeptides adhering to silicone surface, comprising the following steps of: a) obtaining and/or providing a sample from a mammal, wherein said sample is suspected to contain silicone-adhering polypeptides and, optionally, contains silicone; b) contacting said sample with at least one 5 silicone, c) isolating, preferably comprising eluting, said polypeptides that are adhered to said silicone from step a) and/or b); and d) identifying said isolated silicone-adhering polypeptides. In a further aspect thereof, the present invention relates to a reagent kit for identifying 10 polypeptides adhering to a silicone surface, comprising materials, buffers and auxiliary agents and substances for performing a method according to the present invention. In a further aspect thereof, the present invention provides silicone-adhering polypeptides identified through a method or by using a kit according to the present invention. 15 In one preferred embodiment, the present invention relates to a polypeptide identified according to the present invention or a substance that interferes with the binding of a silicone adhering protein and/or polypeptide to a silicone identified according to the present invention, and respective uses thereof. 20 In another preferred embodiment, the present invention relates to a pharmaceutical composition comprising at least one silicone-adhering polypeptide or a substance that interferes with the binding of a silicone-adhering protein and/or polypeptide to a silicone identified according to the present invention, and a pharmaceutical carrier. 25 In another preferred embodiment, the present invention provides a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, and SEQ ID NO. 4 or a functional variant thereof. 30 In yet another preferred embodiment, the present invention relates to a nucleic acid comprising a nucleotide sequence encoding for a polypeptide according to the present invention, in particular for a polypeptide having the amino acid sequence set forth in any one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, or SEQ ID NO. 4, or a functional variant thereof, or a complementary nucleotide sequence of said nucleic acid.
WO 2007/082757 PCT/EP2007/000442 -9 In yet another preferred embodiment, the present invention relates to a nucleic acid that hybridizes under stringent conditions with the nucleic acid according to the present invention. In another preferred embodiment the present invention provides a recombinant vector, 5 comprising the nucleic acid according to the present invention. In a preferred further embodiment, the present invention concerns a host cell comprising a nucleic acid or vector or an expression vector according to the present invention. In a further preferred embodiment, the present invention relates to an antibody that immunologically recognizes a polypeptide according to the present invention. In another preferred embodiment, the present invention 10 provides a polypeptide, a nucleic acid or vector or an expression vector according to the present invention for use in medicine. In another preferred embodiment the present invention relates to an antibody that immunologically recognizes a polypeptide comprising an amino acid sequence selected from 15 the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, and SEQ ID NO. 4 or a functional variant thereof. In one further preferred embodiment, the present invention concerns a pharmaceutical composition, comprising an effective dose of a polypeptide according to the present 20 invention, a nucleic acid or vector according to the present invention, an expression vector according to the present invention, a host cell according to the present invention, or an antibody according to the present invention, and a pharmaceutically acceptable carrier. In a further preferred embodiment, the present invention relates to the use of a polypeptide 25 according to the present invention, a nucleic acid or vector according to the present invention, an expression vector according to the present invention, a host cell according to the present invention, or an antibody according to the present invention for detecting a response reaction of a mammal to a silicone, in particular to a medical silicone. 30 In yet another preferred embodiment, the present invention concerns the use of a polypeptide for detecting a response reaction of a mammal to a silicone, wherein said polypeptide is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO.3, SEQ ID NO.4, Myeloid related protein 8, Myeloid related protein 14, HT018, and PR02619 or a functional variant thereof.
WO 2007/082757 PCT/EP2007/000442 -10 In another preferred embodiment, the present invention relates to a method for detecting a response reaction of a mammal to a silicone, comprising the steps of: a) providing a sample from a mammal to be diagnosed suspected of containing at least one silicone-adhering 5 polypeptide or a functional variant thereof, b) detecting the presence or a change in expression of said at least one silicone-adhering polypeptide or said functional variant thereof in said sample; and c) concluding from said presence or change in expression of said at least one silicone-adhering polypeptide or a functional variant thereof on a response reaction of said mammal to said silicone. 10 In a further preferred embodiment, the present invention relates to a diagnostic kit for detecting a response reaction in a mammal against silicone, in particular medical silicone, comprising materials, buffers, auxiliary agents, and substances for performing a method according to the present invention. 15 In another preferred embodiment, the present invention relates to a method for monitoring a response reaction of a mammal to a silicone, in particular medical silicone, comprising a) implanting at least one silicone into said mammal, and b) detecting the presence or a change in expression of a silicone-adhering polypeptide according to the present invention using a 20 method or kit according to the present invention, and optionally, repeating step b). In another preferred aspect thereof, the present invention provides a method for screening substances that interfere with at least one silicone-adhering polypeptide, comprising the steps of a) providing a substance, wherein said substance is suspected to interfere with the adhering 25 properties of a silicone-adhering polypeptide; b) providing a silicone, in particular a medical silicone; c) providing a silicone-adhering polypeptide; and, d) analyzing the interfering properties of said substance through analyzing the adhesion of said silicone-adhering polypeptide to said silicone in the presence and absence of said substance, wherein a change in the adhesion of said silicone-adhering polypeptide to said silicone in the presence and 30 absence of said substance is indicative for a substances that interferes with the binding of a silicone-adhering protein and/or polypeptide to a silicone. In another preferred aspect thereof, the present invention relates to a method for detecting adhesion of cells to a silicone, comprising a) providing a sample of serum or wound bed fluid WO 2007/082757 PCT/EP2007/000442 -11 of a mammal containing cells; b) providing a silicone; and c) analyzing the amount or number of cells from said serum or wound bed fluid that adhere to said silicone. In another preferred embodiment, the present invention provides a method of treating a 5 mammal suffering from an adverse reaction to an implanted silicone, comprising administering to said mammal an effective amount of a substance interfering with the adhering properties of a silicone-adhering polypeptide as identified through a method according to the present invention. 10 In another preferred embodiment the present invention provides a method for monitoring the treatment of a mammal suffering from a response reaction to a silicone, comprising: a) administering to said mammal an effective amount of a substance interfering with the adhering properties of a silicone-adhering polypeptide as identified according to the present invention b) obtaining a sample from said mammal; and c) detecting the presence or a change 15 in expression of at least one silicone-adhering polypeptide or a functional variant thereof. DETAILED DESCRIPTION Before the present invention is described in more detail below, it is to be understood that this 20 invention is not limited to the particular methodology, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly 25 understood by one of ordinary skill in the art. For the purposes of the present invention, all references as cited herein are incorporated by reference in their entireties. As outlined above there is a need in the prior art to identify polypeptides which are involved for a response reaction of a mammal to a silicone. These polypeptides presumably play a role 30 as key activators of the immune response, which is in turn responsible for the fibrosis leading to implant failure. Thus, a detailed analysis of their composition and the dynamics of their deposition is necessary. Furthermore, these identified polypeptides might serve as both diagnostic as well as potential therapeutic target molecules with respect to the response reaction to silicone.
WO 2007/082757 PCT/EP2007/000442 -12 The term "response reaction" as used herein, shall mean the physiological reaction of a body or a cell to a silicone, such as a medical silicone. Such reaction can manifest itself as an immunological response involving the immune system of the body, and can be present as a 5 local (i.e. at or closely around the site of the contact with the silicone) or systemic (i.e. generally found in the body, such as, for example, in the blood, serum or other fluids) side effect, for example as a response to an implanted silicone, such as to implanted SMIs [Smalley, D. L., Levine, J. J., Shanklin, D. R., Hall, M. F., and Stevens, M. V. Lymphocyte response to silica among offspring of silicone breast implant recipients. Immunobiology 196, 10 567-574 (1996)]. The local and systemic side effects presumably result in the formation of a fibrotic connective tissue capsule (usually with a foreign-body granuloma formation), fibromyalgia, connective tissue disease (e.g. inflammation), and scleroderma-like fibrotic syndrome. Of note the fibrotic process occurring in response to a silicone implant are a model for other, non-implant associated fibrotic diseases, of which four different types are known: 15 (i) post-necrotic diseases, e.g. hepatic cirrhosis, (ii) inflammatory diseases, e.g. rheumatoid arthritis, (iii) or spontaneous forms, e.g. Dypuytren's contracture and (iv) foreign-body reactions in general (e.g. reactions against implants). The term "hypersensitivity" as used herein, refers to a particular type of (an exaggerated) 20 response reaction of a mammal to silicone, e.g. an adverse reaction of an individual in response to a particular silicone, which, in one embodiment, can only be found in this individual, whereas other individuals might not show any respective response (that is, an individual response to a certain silicone). 25 In a preferred aspect thereof, the present invention provides a method for identifying polypeptides adhering to a silicone surface, comprising the following steps of: a) obtaining and/or providing a sample from a mammal, wherein said sample is suspected to contain silicone-adhering polypeptides and, optionally, contains silicone; b) contacting said sample with at least one silicone, c) isolating, preferably comprising eluting, said polypeptides that 30 are adhered to said silicone from step a) and/or b) and d) identifying said isolated polypeptides. Preferably, the polypeptides are first separated using gel electrophoresis, more preferably two-dimensional gel electrophoresis. Preferably, this step is then followed by a staining procedure known to a person skilled in the art, preferably silver staining. The thus stained polypeptides will be detectable as a polypeptide "spot pattern". This pattern is WO 2007/082757 PCT/EP2007/000442 -13 matched and compared with e.g. a control pattern or with a database, e.g. with the ExPasy database of 2D gels, using a software. Preferably, a polypeptide spot of interest is excised, more preferably the polypeptide spot of interest is excised manually. Then, the excised polypeptide spot is preferably digested to obtain fragments that are suitable to be analyzed by 5 mass spectrometry, e.g. peptide mass fingerprint (PMF) using MALDI-TOF. Preferably, the samples are further analyzed using LIFT-TOF/ TOF MS/MS. More preferably, the results are then confirmed using Western blot analysis as known by a person skilled in the art. The terms "adhere" or "adhesion" as used herein, refers to the firmly sticking of a compound, 10 e.g. a polypeptide to a surface, e.g., the surface of a silicone. This sticking can be performed by both covalent and non-covalent binding between the polypeptide and the silicone. The term "polypeptide", in accordance with the present invention, shall mean a peptide or a protein which encompasses amino acid chains of a given length of at least 10, preferably, 20 15 50, more preferred 30-100 amino acids, wherein the amino acid residues are linked by covalent peptide bonds. However, peptidomimetics of such polypeptides wherein amino acid(s) and/or peptide bond(s) have been replaced by functional analogs are also encompassed by the invention. A most preferred polypeptide is a part of the peptide that is functionally responsible or involved for the adhesion of the polypeptide to silicone. 20 The term "silicone" as used herein, shall encompass all dimethylsiloxane polymers that can be used in a physiological environment, such as the human body. Usually, such silicones show a biocompatibility (i.e. do induce no or only slight immune responses of the body) and preferably have a high physiological acceptance. Such silicones are also known as "medical 25 silicones". Such medical silicones can be used for medical implants, such as, for example, silicones mammary implants or as coatings for medical devices e.g. bypass implants. Such medical silicones suitable to be used according to the present invention are known by the person skilled in the art. Preferred examples of such medical silicones are the silicone types MED1511, MED4860, MED4211, MED360 provided by the company Nusil (Waldbroon, 30 Germany). In a preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to an aspect of the present invention, the sample is selected from a proteinaceous film covering a silicone, urine, pleural- or peritoneal fluid, cerebrospinal fluid, WO 2007/082757 PCT/EP2007/000442 -14 wound bed fluid, or serum. Preferably said sample is selected from a proteinaceous film covering a silicone, serum or wound bed fluid. Preferably said wound bed fluid is preferably obtained with drainage. 5 In a preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention the sample is obtained from a mammal showing a response reaction to silicone. In the context of the present invention, a mammal preferably is a human. 10 In another preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention the sample is obtained from a mammal showing a response reaction selected from the group consisting of a fibrotic disease of one of the following types: (i) post-necrotic diseases, e.g. hepatocirrhosis, (ii) inflammatory diseases, 15 e.g. rheumatoid arthritis, (iii) spontaneous fibrotic diseases, e.g. Dupuytren's contracture, (iv) and foreign-body reaction in general. Such diseases can result in the formation of a fibrotic connective tissue capsule, fibromyalgia, connective tissue diseases, and scleroderma-like fibrotic syndrome. 20 In a further preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention the fibrotic connective tissue capsule is formed through an immunological response. In a preferred embodiment of the method for identifying polypeptides adhering to a silicone 25 surface according to the present invention, the wound bed fluid or serum is provided together with an additional silicone, preferably with a medical silicone. In a preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention the silicone is provided unpolymerized. The term 30 "unpolymerized" as used in accordance with the present invention relates to the state of a silicone, e.g. a medical silicone, which is essentially not polymerized. Unpolymerized silicone usually occurs as a by-product of the polymerization of silicone implants (in particular breast implants) and is believed to cause many of the problems associated with such implants.
WO 2007/082757 PCT/EP2007/000442 -15 In another preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according td the present invention the silicone can be any medical silicone known by the person skilled in the art. Preferably the silicone is selected from the group consisting of the silicone types MED 1511, MED4860, MED42 11, and MED360 provided by 5 the company Nusil (Waldbroon, Germany). In another preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention step d) comprises any method known by the person skilled in the art. Preferably, step d) comprises methods selected from one or two 10 dimensional electrophoresis, Western blot analysis, protein assays suitable to measure the amount and/or presence of said proteins, mass spectrometry, a method suitable for analyzing modifications, e.g. silver staining, advanced glycation end products (AGE) formation, oxidation, antibody arrays, ligand arrays/assays, enzyme immunoassay (EIA, e.g. ELISA), radioimmunoassay (RIA), fluorescence immunoassay (FIA), and Luminex assay. 15 In a preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention, the method further comprises in step e) identifying polypeptides that are suitable as marker polypeptides for detecting a response reaction in a mammal to silicone. Preferably, proteins eluted from proteinaceous film covering explanted 20 silicone are compared to silicone-adhering proteins obtained from wound bed fluid or serum. More preferably, the proteins eluted from the two systems are compared by one and/or two dimensional gel electrophoresis. Preferably, proteins from the two systems are labeled with different fluorochromes that can be excited at specific wavelengths, leading to independent images from a single gel. Nevertheless, also a radioactive detection can be carried out. 25 Respective labels are well known to the person of skill. Preferably, the protein spot patterns are analyzed with any software suitable to analyze such patterns known by a person skilled in the art. Preferably, the protein spot patterns are analyzed with the 'Decyder' software (Amersham Biosciences). 30 In another preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention the response reaction is a hypersensitivity reaction in a mammal to silicone.
WO 2007/082757 PCT/EP2007/000442 -1& In a preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention, step e) comprises: e') comparing polypeptide patterns derived from a separation of said proteins identified from the proteinacous film covering said silicone with polypeptide patterns derived from the separation of silicone 5 adhering polypeptides eluted from wound bed fluid or serum; and e") selecting and analyzing a spot of interest in said pattern. Preferably, the amount of proteins deposited are considered different, if the spot volume ratio between samples exceeded two standard deviations of total spot distribution, most preferably, a spot is defined as present only in a system, if the volume ratio exceeded a threshold of fivefold. 10 In another preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention in step a) the polypeptides are furthermore labeled with different fluorochromes or are radioactive labeled. Preferably the fluorochromes are excitable at specific wavelengths. Any fluorochrome known by the person skilled in the 15 art can be used. Preferably the fluorochromes are selected from the group consisting of 7 aminoactinomycine d (7-AAD), acridine orange, alexa dyes, amino methylcoumarine-acetate (AMCA), Cy-dyes, e.g. Cy2, Cy3, Cy5, Cy7, 4',6-Diamidino-2-phenylindole dihydrochloride (DAPI), fluorescein isothiocyanate (FITC), Hoechst-dyes, e.g., Hoechst 33342, Hoechst 33258, "blue" fluorescence, 5,5',6,6'Tetrachloro-1,1',3,3'-tetraethyl 20 benzimidazolylcarbocyanine iodide (JC-1), peridinin-chlorophyll-protein (PerCP), propidium jodide, rhodamine Red-X, phycoerythrin (R-PE), Aminomethylcoumarin acetate sulfonyl chloride rhodamine -derivate (Texas-Red), and Tetramethyl rhodamine isothiocyanate (TRITC). 25 In a preferred embodiment of the method for identifying polypeptides adhering to a silicone surface according to the present invention in step e") polypeptide spot patterns are analyzed by searching for all spots presented in the polypeptide patterns from polypeptides eluted from silicone and presented in the polypeptide patterns of polypeptides of separated silicone adhering polypeptides eluted from wound bed fluid or serum. 30 In a particular preferred embodiment of the method according to the present invention, the mammal is human.
WO 2007/082757 PCT/EP2007/000442 -17 In a further aspect thereof, the present invention relates to a reagent kit for identifying polypeptides adhering to a silicone surface, comprising materials, buffers and auxiliary agents and substances for performing the method according to the present invention. 5 In a further aspect thereof, the present invention relates to a silicone-adhering polypeptide identified through a method or by using a kit according to the present invention. In a further aspect thereof, the present invention relates to a polypeptide identified according to the present invention or a substance that interferes with the binding of a silicone-adhering 10 protein and/or polypetide to a silicone identified according to the present invention, and respective uses thereof. In a further aspect thereof, the present invention relates to a pharmaceutical composition comprising at least one silicone-adhering polypeptide or a substance that interferes with the 15 binding of a silicone-adhering protein and/or polypeptide to a silicone identified according to the present invention, and a pharmaceutical carrier. In a further aspect thereof, the present invention relates to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID 20 NO. 3, and SEQ ID NO. 4 or a functional variant thereof. The term "functional variants" in the sense of the present invention means polypeptides that are functionally related to the polypeptides of the present invention, i.e. share the common structural or functional feature of the polypeptides, to adhere to silicone. Examples of 25 functional variants are orthologs, i.e. the corresponding polypeptide derived from another organism as human, preferably from non-human mammals such as, for example, monkeys, pigs, mice, and rats. Other examples of functional variants are polypeptides that are encoded by different alleles of the gene, in different individuals or in different organ of an organism. Furthermore, also polypeptides shall be encompassed by said term that have a sequence 30 homology, in particular a sequence identity, of about 70%, preferably about 80%, in particular about 90%, more preferred about 95% to the polypeptide with the amino acid sequence according to the polypeptides of the present invention and/or DNA sequences that are derived from these polypeptide sequences. Included are additions, inversions, substitutions, deletions, insertions or chemical/physical modifications and/or exchanges or parts of the polypeptide in WO 2007/082757 PCT/EP2007/000442 -18 the range of about 1-60, preferably of about 1-30, and most preferred about 1-15 amino acids. Thus, functional variants preferably can encompass domain(s) of the protein that are responsible for the adhesion of said polypeptide to a silicone. 5 In a preferred embodiment of the polypeptide according to the present invention the polypeptide or the functional variant thereof adheres to the surface of a silicone. In another preferred embodiment of the polypeptide according to the present invention, the polypeptide is a fusion protein. 10 The term "fusion protein" as used herein, denotes any polypeptide consisting or comprising of at least two polypeptides not naturally forming such a polypeptide. On the DNA level, the two or more coding sequences are fused in frame. The parts of the fusion protein can be connected and/or spaced apart by linkers (usually peptide linkers or chemical linkers) that are known to 15 the person of skill. In a another aspect thereof, the present invention relates a nucleic acid comprising a nucleotide sequence encoding for a polypeptide according to the present invention, in particular for a polypeptide having the amino acid sequence set forth in any one of SEQ ID 20 NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, or SEQ ID NO. 4, or a functional variant thereof, or a complementary nucleotide sequence of said nucleic acid. The term "functional variants" designates all DNA-sequences that are complementary to a DNA-sequence that hybridize under stringent conditions with a derived reference sequence or 25 parts thereof, and exhibit a similar or identical activity compared to the respective peptide of the present invention. Hybridization conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y., 6.3.1-6.3.6, 1991. Moderate hybridization conditions are defined as equivalent to hybridization in 2X sodium chloride/sodium citrate (SSC) at 30'C, followed by a wash in 1 X SSC, 0.1% SDS at 30 50'C. Highly stringent conditions are defined as equivalent to hybridization in 6X sodium chloride/sodium citrate (SSC) at 45 0 C, followed by a wash in 0.2 X SSC, 0.1 % SDS at 65'C. In a preferred embodiment of the nucleic acid according to the present invention, the nucleic acid is DNA, cDNA, PNA, CNA, RNA or combinations thereof. Furthermore, the nucleic WO 2007/082757 PCT/EP2007/000442 -19 acid molecules of the present invention can be genomic DNA, synthetic DNA, or combinations thereof, and can be double-stranded or single-stranded, the sense- and/or an antisense strand. Segments of these molecules are also considered within the scope of the invention, and can be produced by, for example, the polymerase chain reaction (PCR) or 5 generated by treatment with one or more restriction endonucleases. A ribonucleic acid (RNA) molecule can be produced by in vitro transcription. The nucleic acid molecules of the present invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy 10 of the genetic code, encode the same peptide (for example, the peptides with SEQ ID NOs: 1, 2, 3 or 4). In addition, these nucleic acid molecules are not limited to coding sequences, e.g., they can include some or all of the non-coding sequences that lie upstream or downstream from a coding sequence. 15 The nucleic acid molecules of the invention can be synthesized in vitro (for example, by phosphoramidite-based synthesis) or obtained from a cell, such as the cell of a bacterium or mammal. The nucleic acids can be those of a human but also derived from a non-human primate, mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, dog, or cat. Combinations or modifications of the nucleotides within these types of nucleic acids are also encompassed. 20 In addition, the isolated nucleic acid molecules of the invention can encompass segments that are not found as such in the natural state. Thus, the invention encompasses recombinant nucleic acid molecules incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position 25 other than the natural chromosomal location). Recombinant nucleic acid molecules and uses therefore are discussed further below. Furthermore, the nucleic acid according to the present invention can comprise markers or labels, such as affinity tags, antigen tags, fluorescent groups, quenchers, radioactive groups, 30 dyes, heavy atoms (such as nitrogen), enzymatically detectable groups, enzymatically active groups, etc. All these markers or labels and respective technologies for attaching these are well known to the person of skill.
WO 2007/082757 PCT/EP2007/000442 -20 In another aspect thereof, the present invention provides a nucleic acid that hybridizes under stringent conditions with the nucleic acid according to the present invention. In another aspect thereof, the present invention relates to a recombinant vector comprising a 5 nucleic acid according to the present invention. Therefore, the present invention relates in another embodiment to a vector comprising the nucleic acid molecule of this invention. Such a vector is capable of being introduced or of introducing the nucleic acid into a cell. It is preferred that the polypeptides encoded by the 10 introduced nucleic acids are expressed within the cell upon introduction of the vector. In a preferred embodiment of the recombinant vector according to the present invention, the recombinant vector is a recombinant expression vector, including both overexpression and repression vector. 15 In a preferred embodiment the vector of the present invention comprises plasmids, phagemids, phages, cosmids, artificial mammalian chromosomes, knock-out or knock-in constructs, viruses, in particular adenoviruses, vaccinia viruses, attenuated vaccinia viruses, canary pox viruses, lentivirus (Chang, L.J. and Gay, E.E. (20001) Curr. Gene Therap. 1:237 20 251), herpes viruses, in particular Herpes simplex virus (HSV- 1, Carlezon, W.A. et al. (2000) Crit. Rev. Neurobiol.), baculovirus, retrovirus, adeno-associated-virus (AAV, Carter, P.J. and Samulski, R.J. (2000) J. Mol. Med. 6:17-27), rhinovirus, human immune deficiency virus (HIV), filovirus and engineered versions thereof (see, for example, Cobinger G. P. et al (2001) Nat. Biotechnol. 19:225-30), virosomes, "naked" DNA liposomes, and nucleic acid 25 coated particles, in particular gold spheres. Particularly preferred are viral vectors like adenoviral vectors or retroviral vectors (Lindemann et al. (1997) Mol. Med. 3:466-76 and Springer et al. (1998) Mol. Cell. 2:549-58). Liposomes are usually small unilamellar or multilamellar vesicles made of cationic, neutral and/or anionic lipids, for example, by ultrasound treatment of liposomal suspensions. The DNA can, for example, be ionically 30 bound to the surface of the liposomes or internally enclosed in the liposome. Suitable lipid mixtures are known in the art and comprise, for example, DOTMA (1,2-dioleyloxpropyl-3 trimethylammoniumbromide), and DPOE (dioleoylphosphatidyl-ethanolamine), which both have been used on a variety of cell lines.
WO 2007/082757 PCT/EP2007/000442 -21 Nucleic acid coated particles are another means for the introduction of nucleic acids into cells using so called "gene guns", which allow the mechanical introduction of particles into the cells. Preferably the particles itself are inert, and therefore, are in a preferred embodiment made out of gold spheres. 5 In a further aspect of the present invention, the nucleic acid of the present invention is operatively linked to expression control sequences allowing expression in prokaryotic and/or eukaryotic host cells. The transcriptional/translational regulatory elements referred to above include but are not limited to inducible and non-inducible, constitutive, cell cycle regulated, 10 metabolically regulated promoters, enhancers, operators, silencers, repressors and other elements that are known to those skilled in the art and that drive or otherwise regulate gene expression. Such regulatory elements include but are not limited to regulatory elements directing constitutive expression like, for example, promoters transcribed by RNA polymerase III like , e.g., promoters for the snRNA U6 or scRNA 7SK gene, the cytomegalovirus hCMV 15 immediate early gene, the early or late promoters of SV40 adenovirus, viral promoter and activator sequences derived from, e.g., NBV, HCV, HSV, HPV, EBV, HTLV, MMTV or HIV; which allow inducible expression like, for example, CUP-1 promoter, the tet-repressor as employed, for example, in the tet-on or tet-off systems, the lac system, the trp system; regulatory elements directing tissue specific expression, regulatory elements directing cell 20 cycle specific expression like, for example, cdc2, cdc25C or cyclin A; or the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast a- or a-mating factors. 25 As used herein, "operatively linked" means incorporated into a genetic construct so that expression control sequences effectively control expression of a coding sequence of interest. Similarly, the nucleic acids of the present invention can form part of a hybrid gene encoding additional peptide sequences, for example, a sequence that functions as a marker or reporter. 30 Examples of marker and reporter genes include fp-lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neor, G418r), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding fi-galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT). As with many of the standard procedures associated WO 2007/082757 PCT/EP2007/000442 -22 with the practice of the invention, skilled artisans will be aware of additional useful reagents, for example, additional sequences that can serve the function of a marker or reporter. Generally, the hybrid peptide will include a first portion and a second portion; the first portion being a silicon-adhering polypeptide and the second portion being, for example, the reporter 5 described above or an Ig constant region or part of an Ig constant region, e.g., the CH2 and CH3 domains of IgG2a heavy chain. Other hybrids could include an antigenic tag or His tag to facilitate purification and/or detection. Recombinant nucleic acid molecules can also contain a polynucleotide sequence encoding a silicon-adhering polypeptide operatively linked to a heterologous signal sequence. Such signal sequences can direct the protein to different 10 compartments within the cell and are well known to someone of skill in the art. A preferred signal sequence is a sequence that facilitates secretion of the resulting protein. In order to express cDNAs encoding a polypeptide according to the present invention, one typically subclones a polypeptide according to the present invention cDNA into an expression 15 vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and a ribosome-binding site for translational initiation. Suitable bacterial promoters are well known in the art, e.g., E coli, Bacillus sp., and Salmonella, and kits for such expression systems are commercially available. Similarly eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also 20 commercially available. The eukaryotic expression vector may be, for example an adenoviral vector, an adeno-associated vector, or a retroviral vector. In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the 25 silicon-adhering polypeptide-encoding nucleic acid in host cells. A typical expression cassette thus contains a promoter operatively linked to the nucleic acid sequence encoding the silicon adhering polypeptide and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. Additional elements of the cassette may include, for example enhancers. An expression cassette should also contain a transcription 30 termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes. The particular expression vector used to transport the genetic information into the cell is not WO 2007/082757 PCT/EP2007/000442 -23 particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and fusion expression systems such as GST and LacZ, but there are many more known in the art to the skilled person that can be usefully 5 employed. Expression vectors containing regulatory elements from eukaryotic viruses are typically used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, 10 pAV009/A.sup.+, pMTO1O/A.sup.+, pMAMneo-5, baculovirus pDSVE, pcDNA3.1, pIRES and any other vector allowing expression of proteins under the direction of the SV40 early promoter, SV40 late promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells. Some expression systems have markers that 15 provide gene amplification such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase. Alternatively, high yield expression systems not involving gene amplification are also suitable. The elements that are typically included in expression vectors also include a replicon that 20 functions in E. coli, a gene encoding drug resistance to permit selection of bacteria that harbour recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of eukaryotic sequences. The particular drug resistance gene chosen is not critical, any of the many drug resistance genes known in the art are suitable. The prokaryotic sequences are optionally chosen such that they do not interfere with the 25 replication of the DNA in eukaryotic cells, if necessary. Standard transfection methods can be used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of the receptor, which are then purified using standard techniques. 30 Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA WO 2007/082757 PCT/EP2007/000442 -24 or other foreign genetic material into a host cell. It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the silicone-adhering polypeptide according to the present invention. 5 After the expression vector is introduced into the cells, the transfected cells may be cultured under conditions favoring expression of the silicon-adhering polypeptide, which is recovered from the culture using standard techniques. For example the cells may be burst open either mechanically or by osmotic shock before being subject to precipitation and chromatography 10 steps, the nature and sequence of which will depend on the particular recombinant material to be recovered. Alternatively, the recombinant peptide may be recovered from the culture medium in which the recombinant cells had been cultured. In another aspect thereof, the present invention concerns a host cell comprising a nucleic acid 15 or vector, or an expression vector according to the present invention. The host cells that may be used for purposes of the invention include but are not limited to prokaryotic cells such as bacteria (for example, E coli and B. subtilis), which can be transformed with, for example, recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the polynucleotide molecules of the invention; simple eukaryotic cells like yeast 20 (for example, Saccharomyces and Pichia), which can be transformed with, for example, recombinant yeast expression vectors containing the nucleic acid molecule of the invention; insect cell systems like, for example, Sf9 of Hi5 cells, which can be infected with, for example, recombinant virus expression vectors (for example, baculovirus) containing the nucleic acid molecules of the invention; Xenopus oocytes, which can be injected with, for 25 example, plasmids; plant cell systems, which can be infected with, for example, recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors containing a silicon-adhering polypeptide nucleic acid sequence; or mammalian cell systems (for example, COS, CHO, BHK, HEK293, VERO, HeLa, MDCK, Wi38, and NIH 3T3 cells), which can be 30 transformed with recombinant expression constructs containing, for example, promoters derived, for example, from the genome of mammalian cells (for example, the metallothionein promoter) from mammalian viruses (for example, the adenovirus late promoter and the vaccinia virus 7.5K promoter) or from bacterial cells (for example, the tet-repressor binding its employed in the tet-on and tet-off systems). Also useful as host cells are primary or WO 2007/082757 PCT/EP2007/000442 -25 secondary cells obtained directly from a mammal and transfected with a plasmid vector or infected with a viral vector. Depending on the host cell and the respective vector used to introduce the nucleic acid of the invention the nucleic acid can integrate, for example, into the chromosome or the mitochondrial DNA or can be maintained extrachromosomally like, for 5 example, episomally or can be only transiently comprised in the cells. In another aspect thereof, the present inventions provides an antibody that immunologically recognizes a polypeptide and/or protein according to the present invention. The term "antibody" comprises monoclonal and polyclonal antibodies and binding fragments thereof, 10 in particular Fc-fragments as well as so called "single-chain-antibodies" (Bird R. E. et al (1988) Science 242:423-6), chimeric, humanized, in particular CDR-grafted antibodies, and dia or tetrabodies (Holliger P. et al (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6444-8). Also comprised are immunoglobulin like proteins that are selected through techniques including, for example, phage display to specifically bind to the peptides of the present invention. 15 Preferred antibodies bind to those parts of the peptide responsible for binding to their respective receptor. In another preferred embodiment the present invention relates to an antibody that immunologically recognizes a polypeptide comprising an amino acid sequence selected from 20 the group consisting of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, and SEQ ID NO. 4 or a functional variant thereof. In another aspect thereof, the present inventions relates to a polypeptide, a nucleic acid or vector, or an expression vector according to the present invention for use in medicine. 25 In another aspect thereof, the present inventions concerns to a pharmaceutical composition, comprising an effective dose of a polypeptide according to the present invention, a nucleic acid or vector according to the present invention, or an expression vector according to the present invention, a host cell according to the present invention, or an antibody according to 30 the present invention, and a pharmaceutically acceptable carrier and/or other suitable pharmaceutical auxiliary agents. The production of pharmaceutical compositions, e.g. in form of medicaments with a content at least one of a polypeptide according to the present invention, a nucleic acid or vector WO 2007/082757 PCT/EP2007/000442 -2&s according to the present invention or an expression vector according to the present invention, a host cell according to the present invention or an antibody according to the present invention (in the following simply designated as "active ingredients") and their uses according to the present invention occurs according to standard pharmaceutical technology and methods. For 5 this, the active ingredients, together with pharmaceutical acceptable carriers and/or other suitable pharmaceutical auxiliary agents, are produced into medical forms that suitable for the different indications, and places of administration. Thereby, pharmaceutical compositions can be produced in a manner that the release rate that 10 is desired, e.g. a quick onset and/or a retard- or depot-effect is achieved. Thereby, the pharmaceutical compositions can be an ointment, gel, patch, emulsion, lotion, foam, creme or mixed-phase or amphiphilic emulsion systems (oil/water-water/oil-mix-phase), liposome, transfersome, paste or powder. 15 According to the present invention, the term "auxiliary agent" shall mean any, non-toxic, solid or liquid filling, diluting or packaging material, as long as it does not adversely react and/or interacts with the active ingredients or the patient. Liquid galenical auxiliary agents, for example, are sterile water, physiological saline, sugar solutions, ethanol and/or oils. Galenical auxiliary agents for the production of tablets and capsules, for example, can contain binders 20 and filling materials. Furthermore, the active ingredients according to the invention can be used in the form of systemically employed medicaments. These include parenterals belonging to which are injectables and infusions. Injectables are either present in the form of ampoules or as so-called 25 ready-to-use injectables, e.g. as ready-to-use syringes or disposable syringes, and, in addition, are provided in puncture-sealed bottles. The administration of the injectables can take place in form of subcutaneous (s.c.), intramuscular (i.m.), intravenous (i.v.) or intracutaneous (i.c.) application. In particular the suitable forms for injection can pe produced as crystal suspensions, solutions, nanoparticular or colloidal-disperse systems, such as, for example, 30 hydrosoles. The injectable compositions can further be produced as concentrates that are dissolved or dispersed with aqueous isotonic diluents. The infusions can also be prepared in form of isotonic solutions, fatty emulsions, liposome compositions, micro emulsions. Like the WO 2007/082757 PCT/EP2007/000442 -27 injectables, also infusion compositions can be prepared in form of concentrates for dilution. The injectable compositions can also be applied in form of continuous infusions, both in the stationary as well as in the ambulant therapy, e.g. in form of mini pumps. 5 The active ingredients according to the invention can be bound to a micro carrier or nanoparticle, for example to finely dispersed particles on the basis of poly(meth)acrylates, polylactates, polyglycolates, polyaminoacids or polyetherurethanes. The parenteral compositions can also be modified into a depot preparation, e.g. based on the "multiple unit principle", if an active ingredient according to the invention is embedded in finely divided or 10 dispersed, suspended form or as crystal suspension, or based on the "single unit principle", if an active ingredient according to the invention is included in a medicinal form, e.g. in a tablet or a stick that is subsequently implanted. Often, these implants or depot medicaments in the case of ,,single unit"- and ,,multiple unit"-medicaments consist of so-called biodegradable polymers, such as, for example polyesters of lactic and glycolic acid, polyether urethanes, 15 polyaminoacids, poly(meth)acrylates or polysaccharides. As suitable auxiliary agents for producing of parenterals, aqua sterilisata, substances influencing the value of the pH, such as, for example, organic and inorganic acids and bases as well as their salts, buffer substances for adjusting the value of the pH, isotoning agent, such 20 as, for example, sodium chloride, sodium hydrogen carbonate, glucose and fructose, tensides or surface active substances and emulgators, such as, for example, partial fatty acid esters of polyoxyethylene sorbitane (Tween@) or, for example, fatty acid esters of polyoxyethylene (Cremophor@), fatty oils, such as, for example, peanut oil, soy bean oil, and castor oil, synthetic fatty acid esters, such as, for example, ethyloleate, isopropylmyristate and neutral oil 25 (Miglyol@), as well as polymeric auxiliary agents, such as, for example, gelatine, dextran, polyvinylpyrrolidone, solubility enhancing additives, organic solvents, such as, for example, propyleneglycol, ethanol, N,N-dimethylacetamide, propylenglycole or complex-forming substances, such as, for example, citrate and urea, preservatives, such as, for example, benzoic acid hydroxypropylesters and -methylesters, benzylalcohol, antioxidants, such as, for 30 example, sodiumsulfite and stabilisators, such as, for example, EDTA, can be considered. In suspensions, the addition of thickening agents in order to avoid the setting of the an active ingredient according to the invention, or the addition of tensides, in order to ensure the admixing of the sediment, or of complex forming agents such as, for example, EDTA is WO 2007/082757 PCT/EP2007/000442 -28 possible. Active ingredient complexes can be achieved with different polymers, such as, for example, polyethyleneglycoles, polystyrenes, carboxymethyl cellulose, Pluronics@ or polyethylene glycolsorbite fatty acid esters. For producing lyophilisates, scaffold forming agents, such as, for example, mannit, dextran, sucrose, human albumin, lactose, PVP or 5 gelatines are used. The medical forms that are each suitable can be produced in accordance with manuals and procedures known to the person of skill on the basis of pharmaceutical/physical technologies. 10 A further aspect of the present invention then relates to the respectively produced pharmaceutical composition, comprising an effective dose of at least one of a polypeptide according to the present invention, a nucleic acid or vector according to the present invention or an expression vector according to the present invention, a host cell according to the present invention or an antibody according to the present invention, and a pharmaceutically 15 acceptable carrier. This pharmaceutical composition can be characterized in that the active ingredient is present in form of a depot substance or as precursor together with a suitable, pharmaceutically acceptable diluent or carrier substance as above. According to the present invention, the above pharmaceutical composition can be present in 20 the form of tablets, dragees, capsules, droplets, suppositories, compositions for injection or infusion for peroral, rectal or parenteral use. Such administration forms and their production are known to the person of skill. In another aspect thereof, the present inventions relates to the use of a polypeptide according 25 to the present invention, a nucleic acid or vector according to the present invention, or an expression vector according to the present invention, a host cell according to the present invention, or an antibody the present invention for detecting a response reaction of a mammal to a silicone, in particular to a medical silicone. Preferably a response reaction of a human to a silicone. 30 In another aspect thereof, the present inventions concerns to the use of a polypeptide for detecting a response reaction as described below of a mammal to a silicone, wherein said polypeptide is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID WO 2007/082757 PCT/EP2007/000442 -29 NO.3, SEQ ID NO.4, Myeloid related protein 8, Myeloid related protein 14, HT018, and PR02619 or a functional variant thereof. Since the adhesive properties of polypeptides adhering to silicone in different mammals are 5 indicators of a possible response reaction, a diagnostic strategy can be established by identifying polypeptides prone to response reactions and related complications or adverse reactions. Thus, choosing several candidates, e.g. silicone-adhering polypeptides or nucleic acids encoding silicone-adhering polypeptides, a test system for the detection of these polypeptides and/or nucleic acids can be constructed, e.g. by attaching such polypeptides to 10 the surface of silicone from e.g. serum or through amplification methods, such as, for example rt-PCR. Thereby, polypeptides according to the present invention can be detected with methods known in the art, which comprises, immunological methods like ELISA or Western blotting. 15 Preferably, in one embodiment such test system is based on an ELISA system, a method well known by a person skilled in the art. Production of ELISA system for the measurement of silicone-adhering polypeptides is easy to perform and stable for a long time at room temperature. This would facilitate shipping to end-users in order to use these tests as "point of-care" tests, e.g. in the doctor's office. Preferably, such test system uses serum. Moreover, 20 an ELISA system is a standard procedure in many laboratories. This combination would allow for easy integration into current clinical routine. In another aspect thereof, the present inventions provides a method of diagnosis for detecting a response reaction of a mammal to a silicone, comprising the steps of: a) providing a sample 25 from a mammal to be diagnosed suspected of containing at least one silicone-adhering polypeptide or a functional variant thereof; b) detecting the presence or a change in expression of said at least one silicone-adhering polypeptide or a functional variant thereof in said sample; and c) concluding from said presence or change in presence or change in expression of at least one silicone-adhering polypeptide or a functional variant thereof on a 30 response reaction of said mammal to said silicone. In another preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention, the silicone-adhering polypeptide is selected from the group consisting of a polypeptide according to the present WO 2007/082757 PCT/EP2007/000442 -30 invention, Myeloid related protein 8, Myeloid related protein 14, HTO 18, and PR02619 or a polypeptide identified according by a for identifying polypeptides adhering to silicone surface according to the present invention, or functional variants thereof. 5 In another preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention the silicone-adhering polypeptide is detected together with at least one additional silicone-adhering protein and/or polypeptide selected from the group consisting of Isotype control, IgG-HRP, IgE-HRP, and IGA-HRP, AMBP protein precursor, Plasma-retinol binding protein, Kininogen, Eosinophil 10 peroxidase, Fibroblast growth factor 11, TGF-p, Integrin-P4, T-cell receptor, NADH dehydrogenase, Coagulation factor V, ax-spectrin, Monocyte chemotactic protein-2, y glutamyltransferase, Immunoglobulin G, Immunoglobulin A, Complement C3, Complement C2, Complement Cls, C reactive protein, Alpha 1-microglobulin/bikunin precursor, Von Willebrandt Factor, Fibronectin, Vitronectin, Fibrinogen, Collagen I, Collagen III, Collagen 15 IV, Collagen VII, Procollagen III, Laminin, Matrixmetalloproteinase 2, Apolipoprotein 4, Apolipoprotein Al, Ceruloplasmin, Thyreotyrein, Albumin, Alpha .2-macroglobulin precursor, Haptoglobin 1, a and p globin chains, Actin, and HSP 60, Apolipoprotein E3, Complement C2 precursor, Complement C3 precursor, Haemoglobin, Transthyretin or functional variants thereof. 20 In a preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention the presence or a change in expression of the silicone-adhering polypeptide(s) Immunoglobulin G, C-reactive protein, Fibronectin, Collagen I, Procollagen III, Complement C3 precursor, and Myeloid related 25 protein 14 or functional variants thereof is/are detected. Preferably, the presence or a change in expression of the silicone-adhering polypeptides Immunoglobulin G, C-reactive protein, Fibronectin, Collagen I, Procollagen III, Complement C3 precursor, and Myeloid related protein 14 or functional variants thereof are detected. The combination in detection the presence or a change in expression of the silicone-adhering polypeptide Immunoglobulin G, 30 C-reactive protein, Fibronectin, Collagen I, Procollagen III, Complement C3 precursor, and Myeloid related protein 14 increases the sensitivity, specificity, positive and negative predictive value for detecting a response reaction of a mammal to a silicone.
WO 2007/082757 PCT/EP2007/000442 -31 In a further preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention, the sample from said mammal is serum and/or wound bed fluid. 5 In another preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention, the sample is collected before or after implantation of a silicone that is suitable for long-term implantations and coating of medical devices. 10 In a preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention, the method further comprises a second sample as a control, wherein said control is either obtained from the same mammal before or after implantation, or from a different mammal without any implantations of a medical silicone. 15 In another preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention, for detecting silicone-adhering polypeptides or a functional variants thereof antibodies are used suitable to immunologically recognize said polypeptide or functional variant thereof. 20 In a further preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention, the polypeptide or functional variant thereof are detected by one-or two-dimensional gel electrophoresis and/or ELISA. 25 In a preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention, the method further comprises detecting the presence or amount of at least one nucleic acid having a nucleotide sequence encoding for a silicone-adhering polypeptide according to the present invention. 30 In another preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention, said nucleic acid is detected by PCR, RT-PCR or gel electrophoresis.
WO 2007/082757 PCT/EP2007/000442 -32 In a further preferred embodiment of the method of diagnosis for detecting a response reaction of a mammal to a silicone according to the present invention, said method further comprises step a') between step a) and b) which comprises contacting said sample with a silicone under conditions that allow for adhering of said polypeptides to said silicone. 5 In another aspect thereof, the present inventions relates to a diagnostic kit for detecting a response reaction of a mammal to a silicone comprising materials, buffers, auxiliary agents, and substances for performing a method according to the present invention. 10 The term "diagnostic kit" as used herein, shall mean a reagent kit comprising a polypeptide, a nucleic acid molecule, a vector, a host cell, or an antibody of the present invention or as identified or characterized by a method of the present invention. Preferably the reagent kit further comprises reaction buffer(s), storage solutions and/or remaining reagents or materials required for the conduct of scientific or diagnostic assays or the like. Furthermore, parts of the 15 kit of the invention can be packed individually in vials or bottles or in combination in container or multi-container units. In another aspect thereof, the present inventions relates to a method for monitoring a response reaction of a mammal to a silicone, in particular medical silicone, comprising a) implanting at 20 least one silicone into said mammal, and b) detecting the presence or a change in expression of a silicone-adhering polypeptide according to the present invention using a method or kit according to the present invention, and optionally, repeating step b). In yet another aspect thereof, the present inventions concerns a method for screening 25 substances that interfere with at least one silicone-adhering polypeptide, comprising the steps of a) providing a substance, wherein said substance is suspected to interfere with the adhering properties of a silicone-adhering polypeptide; b) providing a silicone, in particular a medical silicone; c) providing a silicone-adhering polypeptide; and d) analyzing the interfering properties of said substance through analyzing the adhesion of said silicone-adhering 30 polypeptide to said silicone in the presence or absence of said substance, wherein a change in the adhesion of said silicone-adhering polypeptide to said silicone in the presence and absence of said substance is indicative for a substance that interferes with the binding of a silicone adhering protein and/or polypeptide to a silicone.
WO 2007/082757 PCT/EP2007/000442 -33 In one embodiment of method for screening active substances that interfere with at least one silicone-adhering protein polypeptide according to the present invention, the silicone-adhering polypeptide is selected of a group consisting of a polypeptide according to the present invention, Myeloid related protein 8, Myeloid related protein 14, HT018, PR02619, a 5 polypeptide identified according to the present invention, Isotype control, IgG-HRP, IgE HRP, and IGA-HRP, AMBP protein precursor, Plasma-retinol binding protein, Kininogen, Eosinophil peroxidase, Fibroblast growth factor 11, TGF-p, Integrin-p4, T-cell receptor, NADH dehydrogenase, Coagulation factor V, a-spectrin, Monocyte chemotactic protein-2, y glutamyltransferase, Immunoglobulin G, Immunoglobulin A, Complement C3, Complement 10 C2, Complement Cls, C reactive protein, Alpha 1-microglobulin/bikunin precursor, Von Willebrandt Factor, Fibronectin, Vitronectin, Fibrinogen, Collagen I, Collagen III, Collagen IV, Collagen VII, Procollagen III, Laminin, Matrixmetalloproteinase 2, Apolipoprotein 4, Apolipoprotein Al, Ceruloplasmin, Thyreotyrein, Albumin, Alpha 2-macroglobulin precursor, Haptoglobin 1, a and P globin chains, Actin, and HSP 60, Apolipoprotein E3, 15 Complement C2 precursor, Complement C3 precursor, Haemoglobin, Transthyretin or functional variants thereof. In another aspect thereof, the present invention provides a method for detecting adhesion of cells to a silicone, comprising a) providing a sample of serum or wound bed fluid of a 20 mammal containing cells; b) providing a silicone; and c) analyzing the amount or number of cells from said serum or wound bed fluid that adhere to said silicone. In a preferred embodiment of the method for detecting adhesion of cells to a silicone according to the present invention, the mammal is human. 25 In a preferred embodiment of said method for detecting adhesion of cells to a silicone according to the present invention the silicone can be any medical silicone known by the person skilled in the art. Preferably, the silicone is selected from the group comprising medical silicone types MED1511, MED4860, MED4211, and MED360 provided by the 30 company Nusil (Waldbroon, Germany). In another aspect thereof, the present invention relates to a substance that interferes with the binding of a silicone-adhering protein and/or polypeptide to a silicone, identified according to a method according to the present invention.
WO 2007/082757 PCT/EP2007/000442 -34 In a further aspect thereof, the present invention provides a method for producing a pharmaceutical composition, comprising a method according to a method according to the present invention, and formulating said substance into a pharmaceutical composition. 5 In a further aspect thereof, the present invention relates to a pharmaceutical composition comprising a substance according to the present invention or that is produced according to the present invention. 10 In another aspect thereof, the present inventions provide a method of treating a mammal suffering from an adverse reaction to an implanted silicone, comprising administering to said mammal an effective amount of a substance interfering with the adhering properties of a silicone-adhering polypeptide as identified through a method according to the present 15 invention. Preferably said effective amount of a substance interfering with a silicone-adhering polypeptide is administered in the form of a pharmaceutical composition, those compositions are well known by a person skilled in the art. In a preferred embodiment of the method of treating a mammal suffering from a response 20 reaction to an implanted silicone according to the present invention, the adverse reaction is a silicosis and/or silicone-related fibrosis. In another aspect thereof, the present inventions relates to a method for monitoring the treatment of a mammal suffering from a response reaction to a silicone, comprising: a) 25 administering to said mammal an effective amount of a substance interfering with the adhering properties of a silicone-adhering polypeptide as identified according to the present invention, b) obtaining a sample from said mammal; c) detecting the presence or a change in expression of at least one silicone-adhering polypeptide or a functional variant thereof. 30 In a preferred embodiment of the method for monitoring the treatment of a mammal suffering from a response reaction to an implanted silicone according to the present invention, the sample is serum or wound bed fluid of a mammal, preferably of a human.
WO 2007/082757 PCT/EP2007/000442 -35 In a preferred embodiment of the method for monitoring the treatment of a mammal suffering from a response reaction to an implanted silicone according to the present invention the silicone-adhering polypeptide is selected of a group consisting of a polypeptide according to the present invention, Myeloid related protein 8, Myeloid related protein 14, HT018, 5 PR02619, a polypeptide identified according to the present invention, Isotype control, IgG HRP, IgE-HRP, and IGA-HRP, AMBP protein precursor, Plasma-retinol binding protein, Kininogen, Eosinophil peroxidase, Fibroblast growth factor 11, TGF-p, Integrin-p4, T-cell receptor, NADH dehydrogenase, Coagulation factor V, a-spectrin, Monocyte chemotactic protein-2, y-glutamyltransferase, Immunoglobulin G, Immunoglobulin A, Complement C3, 10 Complement C2, Complement Cls, C reactive protein, Alpha 1-microglobulin/bikunin precursor, Von Willebrandt Factor, Fibronectin, Vitronectin, Fibrinogen, Collagen I, Collagen III, Collagen IV, Collagen VII, Procollagen III, Laminin, Matrixmetalloproteinase 2, Apolipoprotein 4, Apolipoprotein Al, Ceruloplasmin, Thyreotyrein, Albumin, Alpha 2 macroglobulin precursor, Haptoglobin 1, a and P globin chains, Actin, and HSP 60, 15 Apolipoprotein E3, Complement C2 precursor, Complement C3 precursor, Haemoglobin, Transthyretin or functional variants thereof. The present invention shall now be described further in the following examples with respect to the attached drawings without being limited thereto. For the purposes of the present 20 invention, all references as cited herein are incorporated by reference in their entireties. DESCRIPTION OF THE FIGURES Figure 1. Construction scheme of the ELISA system for protein adhesion to silicone. A 96 25 well plate was coated with silicone and sterilized as described. It was then incubated with serum samples (complemented with protease inhibitors) for 4 days and washed with PBS and water. Adhering proteins were detected using specific primary antibodies and appropriate secondary antibodies labeled with enzyme (e.g. horseradish peroxidase) converting uncolored substrate into a colored product that was measured at a specific wavelength. The amount of 30 protein was directly proportional to the intensity of the developed dye. The assay can be performed in various other formats. Figure 2. Proof of principle screen of patients with fibrotic complications upon implantation of SMIs. Following the ELISA principle as shown in Figure 1, 12 protein candidates in 10 WO 2007/082757 PCT/EP2007/000442 -3& patients (5 with and 5 without fibrotic complications), 7 controls (age and sex matched) and one patient with fluid silicone injection causing dramatic generalized fibrotic complications were tested. (A) Photo of a plate with protein candidates tested. Green coloration indicated high abundance of protein. The variations in protein deposition could generally be 5 distinguished macroscopically. However, absorption measurements of each well were performed for exact quantification and statistical analysis of results. (B) Statistical analysis of different patient groups. After the absorption was measured, values were expressed as means ± standard deviations for each group. The Kolmogorov-Smirnoff test was used to test the normality of the distribution, and t-test was used to calculate p-values. A significant positive 10 correlation of the occurrence of a fibrotic complication with the deposition of fibronectin 1, C-reactive protein (CRP) and IgA, and significant negative correlation with the deposition of complement component C3 and IgG was found. Figure 3. Algorithm of ex vivo and in vitro protein adhesion analysis. In ex vivo analysis 15 saline-filled explanted SMIs were cut in pieces, washed, and adhering proteins eluted in a buffer appropriate for downstream analysis (either for Western blot or for 2D electrophoresis/MS). For in vitro analysis standardized pieces of silicone cut out of new, intact, sterile saline-filled SMIs were incubated for 4 days with WBF or serum. They were then washed in exactly the same way as ex vivo prepared SMIs, and proteins eluted in an 20 appropriate buffer for downstream analysis (either for Western blot or for 2D electrophoresis/MS). For comparison, all protein amounts were normalized per unit of surface. Figure 4. Adhesion of foreskin fibroblasts to silicone coated with serum proteins. Human 25 primary fibroblasts were grown out from foreskin preparations. After their phenotype homogeneity had been determined (data not shown), they were cultured under standard conditions. 96-well plates were coated with silicone, while uncoated polystyrene plates were taken as control. Both were incubated with serum for 4 days and extensively washed with PBS and water. Fibroblasts were then seeded onto both silicone-coated and uncoated plastic 30 wells and eluted at various time points between 15 and 300 minutes. Stronger adhesion of fibroblasts to silicone-coated than to uncoated wells (statistically significant after 240 min *p<0.05, and highly significant after 300 minutes **p<0.001) could be observed. This indicated that preferential adhesion of protein from serum to silicone promoted fibroblast adhesion.
WO 2007/082757 PCT/EP2007/000442 -37 Figure 5. Retrospective case control study, based on a preferred embodiment of the method and kit of the present invention. ELISAs of patients with extensive fibrosis (group 1, BS >3; N=40; median age 51 years, left bars) and patients without extensive fibrosis (group 2, BS <3; 5 N=50; median age 47 years)" are depicted 9 patients thereof (=reactors, 18%; "corrected control", right bars) exhibited a profile as with group 1, and 41 patients thereof did not (=non reactors, middle bars). EXAMPLES 10 Example 1: Construction of an in vitro system for screening of proteins adhering to various silicone types in vivo The principle of protein preparation and analysis is shown in Figure 3. 15 1. Proteins eluted ex vivo The inventors have analyzed proteins deposited on SMIs explanted from women suffering from complications after breast augmentation for cosmetic reasons. Thirteen explanted SMIs were obtained from the Clinic for Plastic and Reconstructive Surgery, Medical University 20 Innsbruck (MUI, Innsbruck, Austria). Nine SMIs were gel and 4 saline filled. Eleven SMIs were rough and 2 smooth surfaced. Only intact implants, i.e. without silicone 'gel bleeding', were considered for analysis. They were taken under sterile conditions immediately after surgery. The fibrotic capsule was removed in the surgical theatre, and SMIs were transported to the laboratory in phosphate buffered saline (PBS, pH 7.2) supplemented with protease 25 inhibitors. Explanted SMIs were washed with PBS (3xl5min) and distilled water (5xl0min) at 4 0 C. After washing, proteins were eluted either in urea lysis buffer [7M urea, 2M thiourea (both from Calbiochem, Bad Soden, Germany), 30mM TRIS, 4% CHAPS, pH 8.5], if they were going to be analyzed by 2D electrophoresis. For Western blot analysis, they were prepared in SDS buffer (2%SDS, 100mM DTT, 50mM TrisCl, 10% Glycerol, pH 9.0). 30 Protein concentration was measured by the bicinchoninic acid protein assay (Pierce Biotechnology: Rockford, IL, USA), and protein solutions were stored frozen at -20 0 C until analysis.
WO 2007/082757 PCT/EP2007/000442 -38 2. Proteins eluted in vitro As silicone types MED1511, MED4860, MED4211, MED360 (NUSIL; Waldbroon, Germany) do not contain or require organic solvents or high temperatures for polymerization, they were tested first. Their physical characteristics made them compatible with polystyrene 5 flat bottom plates routinely used in laboratory practice that we employed in order to have controlled and standardized conditions. All silicone types tested were unrestricted types, i.e. they were certified from producer for long-term implantation by the silicone manufacturer (Nusil; Waldbronn, Germany). They also represented silicone types that are widely used in SMI manufacturing and coating of medical devices. Other silicone types are planned by the 10 inventors to be tested in the future, and the design of the test will be adjusted according to their chemical composition. Five ml of unpolymerized silicone was added per well of 6 well polystyrene plates (Greiner, Frickenhausen, Germany), and plates were immediately centrifuged for various times, 15 depending on the silicone type (MED 1511: 10 min at 300 x g; MED 4860: 60 min at 1 000g; MED 4211: 10 min at 150 x g) in order to distribute silicone evenly on the bottom of the plate. After silicone curing (3 days at 37 0 C and 98% humidity), plates were sterilized for 120 seconds under 200 mJoules of UV light (GsGene UV chamber, Biorad, Hercules, CA) and incubated with wound bed fluid (WBF) taken 2 days after breast augmentation surgery in 20 order to allow for saturation of protein binding sites in the tubing. WBF was supplemented with protease inhibitors (pepstatin, leupeptin, aprotinin from Sigma at final concentration 1 ptg/ml) and incubated with silicone coated plates for 4 days. Within this time, the equilibrium of protein deposition on the surface of silicone was reached while no spontaneous protein degradation occurred. Plates were then washed (10xl5min) in PBS and (5x10 min) distilled 25 H 2 0 at 4'C, and proteins eluted in the same way as the ex vivo protein elution described above. Figure 3 shows the model for in vitro protein adsorption and analysis. 3. Differential analysis of proteins eluted ex vivo and in vitro To determine, if the in vitro model corresponds to the situation ex vivo, the inventors 30 compared proteins eluted from the two systems by one and two-dimensional gel electrophoresis. For differential analysis, the inventors needed a sensitive analytical tool and that is why the DIGETM (Amersham Biosciences, Upsala Sweden) system was employed. Proteins from the two systems were labelled with different fluorochromes that can be excited at specific wavelengths. This experimental setup allowed the inventors to obtain three WO 2007/082757 PCT/EP2007/000442 -39 independent images from a single gel, greatly reducing gel to gel variation and enhancing statistical analysis of the spot patterns. Protein spot patterns were analyzed with the 'Decyder' software (Amersham Biosciences). The amount of proteins deposited was considered different, if the spot volume ratio between samples exceeded two standard deviations of total 5 spot distribution. More stringently, it was defined as present only in either the ex vivo or the in vitro system, if the volume ratio exceeded a threshold of fivefold. Using this approach, the inventors detected so far a total of 184 protein spots. Of these, 163 spots were present in the same amounts in both systems, 13 proteins bound stronger in the ex vivo and 5 in the in vitro system, and only 5 spots were unique for either of the systems. In other words, 89% of protein 10 deposited in vivo are also deposited in our in vitro system. Using mass spectrometry, the inventors identified most of the remaining 11% of proteins and found that they mainly represented intracellular proteins. These findings suggested that additional proteins found in vivo originated from the surrounding damaged tissue as a consequence of the surgical procedure. 15 4. Protein identification 2D electrophoresis Proteins eluted in vitro and ex vivo were primarily analyzed after separation by two dimensional gel electrophoresis (2D electrophoresis) [Anderson, L. and Anderson, N. G. High 20 resolution two-dimensional electrophoresis of human plasma proteins. Proc. Natl. Acad Sci. U S A 74, 5421-5425 (1977)]. For the first dimension separation, proteins were dissolved in urea lysis buffer [7M urea, 2M thiourea (both from Calbiochem, Bad Soden, Germany), 30mM TRIS, 4%CHAPS, pH 8.5]. Prior to loading, 200pjg of total protein was supplemented with rehydration buffer (7M urea, 2M thiourea, 4% CHAPS, 18mM DTE) to a final volume 25 of 350 pl. The inventors then added resolyte buffer and loaded proteins on to 18 cm IPG strips pI 3-11. Proteins were focused for a total of 55000 Vhrs (IPGphor, Amersham Biosciences). After isoelectric focusing, proteins on strips were reduced (2% DTT, 15 min) and subsequently alkylated (2.5 % IAA, 15 min). Second dimension electrophoresis was performed under reducing conditions, in 20x24 cm gradient 9-16% polyacrylamide gels at 30 16 0 C. After 2D electrophoresis, gels were fixed and silver stained according to the Farmer's procedure [Wray, W., Boulikas, T., Wray, V. P., and Hancock, R. Silver staining of proteins in polyacrylamide gels. Analytical Biochemistry 118, 197-203 (1981)]. Pattern matching and mass spectrometry WO 2007/082757 PCT/EP2007/000442 -40 Silver stained protein spot patterns were matched and compared to the ExPasy database of 2D gels (http://us.expasy.org/ch2d/) using the 'Melanie' software (version 4, Swiss Institute of Bioinformatics, Basel, Switzerland) [Hughes, G. J., Frutiger, S., Paquet, N., Ravier, F., Pasquali, C., Sanchez, J. C., James, R., Tissot, J. D., Bjellqvist, B., and Hochstrasser, D. F. 5 Plasma protein map: an update by microsequencing. Electrophoresis 13, 707-714 (1992)]. Spots of interest were manually excised, proteins digested with trypsin (Promega, Mannheim, Germany), and peptides analyzed by Mass spectrometry (Ultraflex TM TOF/TOF, BrukerDaltonics, Billerica, MA). 10 In gel digestion was performed as described by Shevchenko et al. [Shevchenko, A., Wilm, M., Vorm, 0., and Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Analytical Chemistry 68, 850-858 (1996)]. Those samples which were analyzed by peptide mass fingerprint (PMF) from MALDI-TOF were additionally analyzed using LIFT-TOF/TOF MS/MS from the same target. A maximum of three precursor ions per 15 sample were chosen for MS/MS analysis. PMF was measured with reflector mode, followed MALDI-TOF/TOF measurement with LIFT mode. PMF spectra were interpreted with the 'Mascot' and 'Profound' software. The probability score higher than 64 for 'Mascot' and 1.65 for 'Profound' was used as a cut-off criterion for the correct identification. 20 Confirmation of results with Western Blots To complement and confirm the data obtained from mass spectroscopy and database search, the inventors performed Western blots of proteins eluted from silicone. For this purpose, the inventors used proteins eluted in SDS buffer (2%SDS, 100mM DTT, 50mM TrisCl, 10% glycerol, pH 9.0) that were loaded to small (7x10 cm) homogenous 12% polyacrylamide gels. 25 After the run, proteins were blotted to on the nitrocellulose membrane for 1200 mAh in a wet blotting chamber, and blocked with 5% fat free milk. Primary antibodies against most of the proteins, as well as appropriate conjugates, were obtained from DAKO, polyclonal rabbit antibodies against Myeloid Related Protein (MRP) 8 and MRP14 were a kind gift from Dr. Claus Kerkhoff (Institute of Experimental Dermatology; Muenster, Germany), and we 30 ourselves produced affinity chromatography purified monoclonal antibodies against human HSP60, from clone 11-13 [Xu, Q., Schett, G., Seitz, C. S., Hu, Y., Gupta, R. S., and Wick, G. Surface staining and cytotoxic activity of heat-shock protein 60 antibody in stressed aortic endothelial cells. Circ. Res. 75, 1078-1085 (1994)]. All antibody dilutions were prepared in 5% fat free milk in PBS. After the secondary antibody incubation membranes were washed WO 2007/082757 PCT/EP2007/000442 41 with PBS and chemiluminescent substrate for horseradish peroxidase (Amersham Biosciences) was added for 1 min. Membranes were exposed to AGFA x-ray films for various times and developed in the Currix developing machine. 5 5. Proteins that have been identified Until recently, the following 47 proteins have been identified in the context of the present invention as adhering to silicone(s): Protein name Actin Albumin Alpha1-microglobulin/bikunin precursor Alpha2-macroglobulin precursor AMBP protein precursor Apolipoprotein Al Apolipoprotein E3 C reactive protein Coagulation factor V Collagen I Collagen IV Collagen VII Complement C Is Complement C2 precursor Complement C3 precursor Eosinophil peroxidase Fibrinogen Fibroblast growth factor 11 Fibronectin Haptoglobin 1 Hemoglobin HSP 60 HT018 IgA Immunoglobulin G Integrin beta 4 Kininogen Laminin Matrix metalloproteinase 2 Monocyte chemotactic protein-2 Myeloid related protein 14 Myeloid related protein 8 NADH dehydrogenase Plasma-retinol binding protin PR02619 Procollagen III T-cell receptor TGF-p Transthyretin Vitronectin WO 2007/082757 PCT/EP2007/000442 42 Von Willebrand Factor a-spectrin y-glutamyltransferase 4 unknown proteins Furthermore, the following proteins were identified by 2D in vivo, 2D in vitro and ELISA (in vitro) and are listed together with their GeneBank accession numbers (* indicates confirmed by Western Blot (WB)) 5 Protein name Acc No. Immunoglobulin G * gil4321905 C reactive protein * p02741 Myeloid related protein 8 * p05109 Fibronectin * p02751 Vitronectin * p04004 Collagen I * gil4502961 Procollagen III q541P8 Laminin * gil27804346 Actin * gi|15277503 Immunoglobulin A * gi|8699307 Complement C3 precursor p01024 The following proteins were identified by 2D in vivo, and ELISA (in vitro) and are listed together with their GeneBank accession numbers (* indicates confirmed by Western Blot (WB)) 10 Protein name Acc No. Myeloid related protein 14 p 0 67 02 Myeloid related protein 14 p 06 7 02 Collagen IV gil180715 The following proteins were identified by 2D in vitro and ELISA (in vitro) and are listed together with their GeneBank accession numbers (* indicates confirmed by Western Blot (WB)) 15 Protein name Acc No. Collagen VII * gi|627406 Matrix metalloproteinase 2 * p08253 Von Willebrand Factor * p04275 Heat shock protein 60 p10809 The following proteins were identified by 2D in vivo and/or 2D in vitro where antibodies were available, but proteins were not detected by ELISA and are listed together with their GeneBank accession numbers (* indicates confirmed by Western Blot (WB)) 20 Protein name Acc No. Complement CIs p09871 Complement C2 precursor * gil67611 TGF-p p01137 T-cell receptor giJ62465548 Albumin gil28592 WO 2007/082757 PCT/EP2007/000442 43 Integrin beta4 * gil21361207 unknown proteinI gil34533774 unknown protein2 gil21739298 unknown protein3 gil21754778 unknown protein4 gil7020569 The following proteins were identified by 2D in vivo and/or 2D in vitro where no antibodies were available, and are listed together with their GeneBank accession numbers (* indicates confirmed by Western Blot (WB)) 5 Protein name Acc No. Haptoglobin 1 p 0 0 73 8 Apolipoprotein Al gil178777 Transthyretin p02766 Alpha2-macroglobulin precursor p01023 Hemoglobin gil55635219 Alpha 1 -microglobulin/bikunin precursor p02760 Fibrinogen * p02671 NADH dehydrogenase gil5138999 HT018 gil9963853 AMBP protein precursor gil179519 Kininogen p01042 Plasma-retinol binding protin gil190870 Coagulation factor V p12259 PR02619 gill1493459 Eosinophil peroxidase gil31183 Fibroblast growth factor 11 gil20160215 a-spectrin gil189071 Monocyte chemotactic protein-2 gil1905801 y-glutamyltransferase gil3282014 Apolipoprotein E3 gil1480096 Classification of the identified silicone-adhering protein The proteins as identified according to the invention can be classified as follows with respect to their biological functions: 10 1) Functional group inflammation: C reactive protein Complement C ls Complement C2 precursor Immunoglobulin G Myeloid related protein 14 Myeloid related protein 8 Von Willebrand Factor IgA Integrin beta 4 Complement C3 precursor Apolipoprotein Al Apolipoprotein E3 Alpha 1 -microglobulin/bikunin precursor HSP 60 WO 2007/082757 PCT/EP2007/000442 44 HT018 PR02619 AMBP protein precursor T-cell receptor 2) Functional group fibrosis: Coagulation factor V Collagen I Collagen IV Fibronectin Laminin Collagen VII Fibrinogen Fibroblast growth factor 11 Kininogen Matrix metalloproteinase 2 Procollagen III Vitronectin 5 3) Functional group inflammation and fibrosis: TGF-p 4) Functional group other: Eosinophil peroxidase Actin Albumin Alpha2-macroglobulin precursor Haptoglobin 1 Hemoglobin Transthyretin y-glutamyltransferase Monocyte chemotactic protein-2 NADH dehydrogenase unknown protein (SEQ ID NO. 1) unknown protein2 (SEQ ID NO. 2) unknown protein3 (SEQ ID NO. 3) unknown protein4 (SEQ ID NO. 4) 10 5. Proteins suitable to discriminate between normal and fibrotic tissue Immunoglobulin G C reactive protein Fibronectin Collagen I Procollagen III Complement C3 precursor Myeloid related protein 14 Profile of proteins differentially adhering to silicone WO 2007/082757 PCT/EP2007/000442 45 Proteins found adhering both ex vivo and in vitro to different selected medical silicone types are summarized in Table 1. Their relative abundance is expressed in the following way: ?: not tested, 0: absent, +: present, ++: abundant, +++: highly abundant. 5 Proteins could be classified into different categories: anchor proteins, a primary protein set, and a secondary protein set. Only the first two categories have been reconfirmed by alternative techniques (Western Blot, ELISA). 1. Proteins of equal, strong adhesion (anchor proteins) 10 These proteins were defined as at least 'abundant', i.e. ++, and presented as equally adhesive towards all silicone types tested. Seven (7) candidates were included into this group. They are marked with the symbol "*" 2. Primary protein set 15 This set consisted of twenty-one (21) proteins. For inclusion they had to be detected in all of the tested silicone types. Three subcategories could be defined: Proteins of equal, but low adhesion Fourteen proteins (14) constituted this subcategory, which was defined as 'present', i.e. +. 20 They are marked with the symbol "V". Proteins of differential silicone type adhesion Seven (7) proteins showed a significant difference in adhesion to the silicone types MED1511, 4860, 4211, and 360 (Nusil). They covered molecules of all adhesion strength, i.e. 25 0, +, ++ and +++. They are marked with the symbol "o". Proteins of unclassified adhesion properties This group of four (4) proteins was tested on two silicone types only. The successful experiments showed adhesion class 'present' (+). So far they would most likely be members of 30 subcategory 1 (proteins with equal, but low adhesion). They are marked with the symbol "U". Table 1. Proteins deposited on the surface of medical grade silicones. Ontology Protein name - set Silicone type 1511 4860 4211 WO 2007/082757 PCT/EP2007/000442 4& Immunoglobulin G - m +++ ++ Immunoglobulin A - m ++ ++ +++ Complement C3 - * ++ ++ ++ Complement C2 - V + + + Complement Cis - m + 0 0 C reactive protein - * ++ ++ ++ Myeloid related protein 8 - m + + 0 Myeloid related protein 14 -V + + Alpha 1-microglobulin/bikunin precursor C-+ + + -V Von Willebrandt Factor - V + + + HT018 - O + ? + Fibronectin - *+++ Vitronectin - * ++ ++ ++ Fibrinogen - * ++ ++ ++ Collagen I - V + + + Collagen IV - V + + + Collagen VII -V + + + Procollagen III - E + + ? Laminin - m +++ ++ ++ Matrixmetalloproteinase 2 - w + 0 + Apolipoprotein 4 - V + + + Apolipoprotein Al - O + ? + Ceruloplasmin -V + + + Thyreotyrein - V + + + Albumin - m ++ +++ ++ Alpha 2-macroglobulin precursor - V + + + Haptoglobin 1 - V + + + a and P globin chains -* +++ +++ Actin - V + + + HSP60-V + + + PR02619 - O + + ? WO 2007/082757 PCT/EP2007/000442 -47 3. Secondary protein set This set consisted of seventeen (17) proteins. They were detected on one silicone type only (MED 1511) and have not been confirmed by techniques other than mass spectrometry. The 5 following thirteen (13) proteins were found in this set: AMBP protein precursor Plasma-retinol binding protein Kininogen Eosinophil peroxidase 10 Fibroblast growth factor 11 TGF-p Integrin - p4 T-cell receptor NADH dehydrogenase 15 Coagulation factor V a-spectrin Monocyte chemotactic protein-2 y-glutamyltransferase 20 Furthermore, there were four (4) unknown Homo sapiens protein products and hypothetical proteins as identified by 'Masscot': Acc. no.: gil34533774; mass: 113642; unknown protein product (SEQ ID NO. 1) Acc. no.: gil21739298, embICAD38696.1; mass: 117490; unknown protein product (SEQ ID NO. 2) 25 Acc. no.: gil21754778; mass: 38453; unknown protein product (SEQ ID NO. 3) Acc. no.: gil7020569; mass: 14004; unknown protein product (SEQ ID NO. 4) Novel protein candidates Among the proteins mentioned above, there were several ones, which so far have not been 30 mentioned in connection with hypersensitivity to silicone and consecutive fibrosis: 1. Myeloid related protein 8 2. Myeloid related protein 14 3. HT018 4. PRO2619 WO 2007/082757 PCT/EP2007/000442 48 5. Acc. no.: gil34533774; mass: 113642; unknown protein product (SEQ ID NO. 1) 6. Acc. no.: gil21739298, embICAD38696.1; mass: 117490; unknown protein product (SEQ ID NO. 2) 7. Acc. no.: gil21754778; mass: 38453; unknown protein product (SEQ ID NO. 3) 5 8. Acc. no.: gil7020569; mass: 14004; unknown protein product (SEQ ID NO. 4) Diagnostic test system It is hypothesized that the adhesion properties of proteins adhering to silicone in different patients are indicators of the possible immune and subsequent fibrotic reactions individuals 10 might have developed. If this hypothesis was correct, the inventors could establish a diagnostic strategy, which identified proteins prone to fibrotic complications. Thus, after having performed protein analyses (see Example 2 and 3), the inventors chose several candidates and constructed a test system for the detection of these proteins recruited to the surface of silicone from serum. 15 Practical advantages 1) The test protocol is based on ELISA microwell plates. Production of this test system is easy to perform and stable for a long time at room temperature. This would facilitate shipping to end-users. 20 2) The test system uses sera. Moreover, an ELISA system is a standard procedure in many laboratories. This combination allows an easy integration into current clinical routine. Technical details Polystyrene 96 well flat bottom microtiter plates were coated with medical silicone types 25 1511, 4860 and 4211. Fifty d of unpolymerized silicone was added per well of 96-well polystyrene plates (Greiner, Frickenhausen, Germany), and plates were immediately centrifuged for various times, depending on the silicone type (MED 1511: 10 min at 300g; MED 4860: 60 min 1000g; MED 4211: 10 min-I50g) in order to distribute silicone evenly on the bottom of the plate. After silicone curing (3 days at 37'C and 98% humidity), plates were 30 sterilized for 120 seconds under 200 mJoules of UV light (GsGene UV chamber, Biorad, Hercules, CA). Following sterilization, silicone coated 96 well plates were incubated with serum from patients before and after undergoing primary breast augmentation or with serum of patients having their SMIs exchanged. All sera are supplemented with 1 pg/ml of leupeptin, pepstatin and aprotinin (protease inhibitors, Sigma-Aldrich, Vienna, Austria), WO 2007/082757 PCT/EP2007/000442 49. filtered through 0.22 tm filters and 100 pul is applied to each well under aseptic conditions. In some experiments, sera were diluted with PBS prior to application. After 50 hours, excess proteins were washed away with 4x 5 min washing with PBS, and further binding sites on the plates blocked with 2.5% BSA/0,1%tween 20 in PBS for 100 minutes at room temperature. 5 One hundred and fifty pl of blocking solution were applied per well. Following blocking, various antibodies were applied in previously determined optimal dilutions in blocking solution. Our initial screen was composed of 24 antibodies, but we reduced our current list to 12 applied in the following optimal working dilutions (Table 2): 10 Table 2. Antibodies used for the modified ELISA system for protein adhesion. Column Antibody against From Dilution Company, serial No. 1 isotype control Mouse 1:1000 DAKO X0931 2 Isotype control Rabbit 1:1000 DAKO X0903 3 Fibronectin Rabbit 1:1000 DAKO A245 4 Collagen I Rabbit 1:500 Calbiochem 234167 5 CRP Rabbit 1:500 DAKO A0073 6 HSP 60 Mouse 1:1000 Supernat. clone 11-13 7 C3 complement Mouse 1:500 DAKO M0836 8 Von Willebrand factor Mouse 1:500 DAKO M0616 9 Collagen III Rabbit 1:500 Chemicon AB 747 10 IgG - HRP Rabbit 1:500 DAKO P 214 11 IgE - HRP Rabbit 1:500 DAKO P 295 12 IgA - HRP Rabbit 1:500 DAKO P 216 It is important to state here that this list of antibodies is, of course, not a final one. It will grow according to the new findings the inventors obtain in the protein analysis of the film formed on the surface of silicone. After incubation with primary antibody, the plate was washed 3x5 15 min PBS, and appropriate secondary antibodies conjugated with HRP were applied for 120min, in 100 pl/well volume, on a shaking platform at room temperature. Wells incubated with directly labeled primary antibodies were kept in PBS until the ABTS development step. The following secondary antibodies were used: Rabbit anti-mouse IgG HRP, DAKO P260, 1:1000 and swine anti-rabbit IgG HRP, DAKO P399, 1:1000. All dilutions were made in 20 blocking solution. After the secondary antibody incubation at room temperature, the plate was washed 3x5 min in PBS/0.02% Tween, and 2 x 5min in pure PBS. The standard ABTS WO 2007/082757 PCT/EP2007/000442 -50 ELISA detection solution for HRP was used to visualize the results. Color was developed for 40 min, the solution moved to new 96 well plates (to exclude silicone coating interference with spectrophotometric measurement), and the absorption measured at 405 nm. Thus, we have constructed an ELISA system for the measurement of protein adhesion to silicone 5 (Figure 1). Titrating different blocking solutions, the inventors managed to significantly reduce the background level. The inventors defined the cut-off for presence of a protein as 2 absorbance values of isotype controls. Background values were less than 1% of probe measurements, the 10 linear range spanning over two orders of magnitude. The whole test system was highly reproducible and allowed for semi-quantitative analysis of the deposited proteins. A major advantage of this system is that simultaneous analysis of large number of patients and various proteins respectively deposited onto silicone is possible in a relatively short time. 15 As a proof of principle (Figure 2), the inventors tested 12 protein candidates in 10 patients (5 with and 5 without fibrotic complications), 7 controls (age and sex matched) and one patient with fluid silicone injection (!) causing dramatic generalized fibrotic complications. We found a significant positive correlation of the deposition of fibronectin, CRP and IgA with fibrosis, and negative correlation with the deposition of complement component C3 and IgG. 20 Thus, the inventors have noticed different pattern of protein deposition from various patients as a proof of principle. In fact, the inventors would like to extend the analysis and correlate the results with implant duration and local or systemic complications on a large cohort of patients. For this purpose, the inventors have adjusted the test system to a 384-well format, 25 which allows for rapid screening and larger clinical studies. Moreover, the amount of sera, which often is a limiting factor for the analysis, can be reduced, saving costs as well as enhancing reproducibility due to the possibility of replication. The detection system with primary antibodies against specific proteins and appropriate HRP conjugated secondary antibodies is the same as above, but in lower volume (50ptl). Colour was developed for 40 30 min, the solution moved to new 384 well plates (to exclude silicone coating interference with spectrophotometric measurement), and the absorption measured at 405 nm on "Victor" 384 well plate spectrophotometer (Perkin Elmer, Boston, USA). Table 3. List of medical grade silicones that can be tested Silicone type Tested Notes WO 2007/082757 PCT/EP2007/000442 51 (Yes/No) MED 1511 Yes Most frequently used MED 4860 Yes Putatively for SMIs MED 4211 Yes Low consistency elastomer MED 360 Yes Liquid MED 4213 No Adhesive MED 4720 No High consistency elastomer MED 4520 No High consistency elastomer MED 2174 No High consistency elastomer MED 4565 No High consistency elastomer MED 4765 No High consistency elastomer MED 4780 No High consistency elastomer MED 2245 No High consistency elastomer MED 4755 No Ultra high tear MED 4770 No Abrasion resistant MED 4801 No LSR eastomer MED 4810 No LSR eastomer MED 4820 No LSR eastomer MED 4830 No LSR eastomer MED 4860 No LSR eastomer MED 6210 No Low consistency elastomer MED 6215 No Low consistency elastomer MED 6385 No Low consistency elastomer MED3 -6300 No gel There are some 20 additional types of unrestricted (certified for long term implantation) silicone types, but this assortment covers all the general types of silicone used for medical purposes. 5 1. Background The differences in adhesion properties of the defined protein array consisting of selected candidates to silicone might be responsible for the variation observed in development of subsequent adverse effects of silicone devices. This system allowed for simultaneous analysis 10 of deposition of seven proteins in a cohort of patients. They were chosen from the screen of the proteome on the surface of silicone according to example 1. In a retrospective study the deposition pattern of this protein array successfully discriminated patients that developed fibrosis versus patients without complications (Figure 5). 15 Interestingly, also among control individuals a subgroup with the deposition pattern analogous to the patients developing fibrosis as a response to silicone was identified. A follow up prospective study is now being conducted to determine if this group would be at potential risk, i.e. predisposed, to strong fibrotic adverse reaction to silicone.
WO 2007/082757 PCT/EP2007/000442 -52 2. Method Ninety women that had breast augmentation exclusively for cosmetic purposes were included in the study. They were separated into two groups according to the Baker Score (BS) of breast 5 connective tissue fibrosis: patients with fibrosis (BS ;3; N=40; median age 51 years), and patients without extensive fibrosis (BS <3; N=50; median age 47 years). The deposition pattern of the 7 different proteins listed below was compared in this cohort study. To normalize the data, absorption values were transformed according to the formula 10 x'=log(x+1). Transformed values had a normal distribution, as tested by Kolmogorov Smimov test. In these experiments, background values were less than 1% of probe measurements, and the linear range of detection was spanning two orders of magnitude. During the analysis, a subgroup within the low fibrotic study branch (18%, n=9) was noticed that had protein deposition profile analogous to the one patients with fibrosis have. They were 15 classified as a separate group of "corrected controls". This observation was confirmed by clustering the data using "Treeview" clustering software. Software clustered these 18% of control patients in a separate group, together with patients with fibrosis. Table 4. Proteins used in this study and their individual p-values 20 In order to discriminate between the study branches (p<0.001) the aggregation of all seven candidates is required Immunoglobulin G 0,047 C reactive protein 0,441 Fibronectin 0,038 Collagen I 0,335 Procollagen III 0,137 Complement C3 precursor 0,173 Myeloid related protein 14 0,033 25 System for testing drugs Preferential adhesion of selected protein candidates to silicone suggests their functional relevance for the development of the hypersensitivity reaction and the associated fibrotic complication. Consequently, one could try to interfere with protein attachment by using drugs, which either covered the adhesion sites for these proteins or captured the candidates 30 before they bound to the silicone surface. Thus, the inventors recommend to use the following test system for a future drug screening application. It is based on polystyrene 384-microwell WO 2007/082757 PCT/EP2007/000442 -53 plates. The principle of silicone coating is almost identical as in 2.4.1.2. The only difference is that 10pl of each unpolymerized silicone was applied per well instead of 50. The amount of serum or any other protein solution applied per well is also significantly smaller, and it is reduced to 20 pd per well. All incubation times remain the same. 5 In vitro cell adhesion to silicone The same system of silicone coated plates was used for cell adhesion experiments. As described above, plates were coated with various silicone types, and either incubated or not with WBF or serum for 4 days. After this period, plates were washed, and 2 ml of 5x10 4 cells 10 /ml suspension in DMEM medium without serum were added per well. At various time points, the nonadherent cells were removed by gentle pipetting, and the remaining cells were fixed in 4% formaldehyde. The relative number of attached cells was determined in a crystal violet assay [Gailit, J., Clarke, C., Newman, D., Tonnesen, M. G., Mosesson, M. W., and Clark, R. A. Human fibroblasts bind directly to fibrinogen at RGD sites through integrin 15 alpha(v)beta3. Experimental Cell Research 232, 118-126 (1997)]. Crystal violet solution was added (0.2% w/v in 2% ethanol), and incubated for 10 minutes at room temperature. Plates were washed two times in tap water by immersion in a large beaker. Then they were drained upside down on paper towels, and 1% SDS was added to solubilize the stain. Plates were agitated on an orbital shaker until the color was uniform with no areas of dense coloration in 20 bottom of wells, and absorbance of 1% SDS solution from each well was read at 562 nm, with 1% SDS as a blank. The solution was measured by classical spectrophotometry. The whole test could be performed on six-well plates and downsized to a 96-well format for high throughput application. Figure 4 shows fibroblast adhesion to the silicone coated plastic wells.

Claims (28)

1. A method for identifying polypeptides adhering to a silicone surface, comprising the following steps of: a) obtaining a sample from a mammal, wherein said sample is suspected to contain silicone-adhering polypeptides and, optionally, contains silicone; 10 b) contacting said sample with at least one silicone; c) isolating said polypeptides that are adhered to said silicone from step a) and/or b); and d) identifying said isolated silicone-adhering polypeptides. 15
2. The method according to claim 1, wherein said sample is selected from a proteinaceous film covering a silicone, wound bed fluid, and serum from a mammal showing a response reaction to implanted silicone.
3. The method according to claim 1 or 2, further comprising 20 e) identifying polypeptides that are suitable as marker polypeptides for detecting a response reaction in a mammal to silicone.
4. The method according to claim 3, wherein step e) comprises: e') comparing polypeptide patterns derived from a separation of said proteins 25 identified from the proteinacous film covering said silicone with polypeptide patterns derived from the separation of silicone-adhering polypeptides eluted from wound bed fluid or serum; and e") selecting and analyzing a spot of interest in said pattern. 30
5. A reagent kit for identifying polypeptides adhering to a silicone surface, comprising materials, buffers and auxiliary agents and substances for performing the method according to any of claims 1 to 4.
6. A silicone-adhering polypeptide, identified through a method according to any of 35 claims 1 to 4. WO 2007/082757 PCT/EP2007/000442 -55
7. Polypeptide, comprising an amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, and SEQ ID NO. 4 or a functional variant thereof, wherein said polypeptide or the functional variant thereof adheres to the 5 surface of a silicone.
8. A nucleic acid comprising a nucleotide sequence encoding for a polypeptide according to claim 6 or 7, or a functional variant thereof, or a complementary nucleotide sequence of said nucleic acid. 10
9. Use of a polypeptide for detecting a response reaction of a mammal to a silicone, wherein said polypeptide is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, Myeloid related protein 8, Myeloid related protein 14, HTO 18, and PR02619, or a functional variant thereof. 15
10. A method for detecting a response reaction of a mammal to a silicone, comprising the steps of: a) providing a sample from a mammal to be diagnosed suspected of containing at least one silicone-adhering polypeptide or a functional variant thereof; 20 b) detecting the presence or a change in expression of said at least one silicone adhering polypeptide or said functional variant thereof in said sample; and c) concluding from said presence or change in expression of said at least one silicone-adhering polypeptide or a functional variant thereof on a response reaction of said mammal to said silicone. 25
11. The method according to claim 9, wherein said silicone-adhering polypeptide is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, Myeloid related protein 8, Myeloid related protein 14, HT018, and PR02619 or a polypeptide identified according to a method according to any of claims 30 1 to 4, or a functional variant thereof.
12. The method according to claim 10 or 11, wherein said silicone-adhering polypeptide is detected together with at least one additional silicone-adhering protein and/or polypeptide selected from the group consisting of Isotype control, IgG-HRP, IgE-HRP, WO 2007/082757 PCT/EP2007/000442 -56 and IGA-HRP, AMBP protein precursor, Plasma-retinol binding protein, Kininogen, Eosinophil peroxidase, Fibroblast growth factor 11, TGF-p, Integrin-p4, T-cell receptor, NADH dehydrogenase, Coagulation factor V, a-spectrin, Monocyte chemotactic protein-2, y-glutamyltransferase, Immunoglobulin G, Immunoglobulin A, 5 Complement C3, Complement C2, Complement Cls, C-reactive protein, Alpha 1 microglobulin/bikunin precursor, Von Willebrandt Factor, Fibronectin, Vitronectin, Fibrinogen, Collagen I, Collagen III, Collagen IV, Collagen VII, Procollagen III, Laminin, Matrixmetalloproteinase 2, Apolipoprotein 4, Apolipoprotein Al, Ceruloplasmin, Thyreotyrein, Albumin, Alpha 2-macroglobulin precursor, Haptoglobin 10 1, a and P globin chains, Actin, and HSP 60, Apolipoprotein E3, Complement C2 precursor, Complement C3 precursor, Haemoglobin, Transthyretin, or functional variants thereof.
13. The method according to any of claims 10 to 12, wherein the presence or a change in 15 expression of the silicone-adhering polypeptide(s) Immunoglobulin G, C-reactive protein, Fibronectin, Collagen I, Procollagen III, Complement C3 precursor, and Myeloid related protein 14 or functional variants thereof is/are detected.
14. The method according to any of claims 10 to 13, wherein said sample from said 20 mammal is serum and/or wound bed fluid, and wherein said sample is collected before or after implantation of a silicone that is suitable for long-term implantations and coating of medical devices.
15. The method according to any of claims 10 to 14, further comprising providing of a 25 second sample as a control, wherein said control is either obtained from the same mammal before or after implantation, or from a different mammal without any implantation of a medical silicone.
16. The method according to any of claims 10 to 15, wherein said method further 30 comprises detecting the presence or amount of at least one nucleic acid having a nucleotide sequence encoding for a silicone-adhering polypeptide according to claim 6 or 7. WO 2007/082757 PCT/EP2007/000442 -57
17. The method according to any of claims 10 to 16, wherein said method further comprises step a') between step a) and step b) which comprises contacting said sample with a silicone under conditions that allow for adhering of said polypeptides to said silicone. 5
18. A diagnostic kit for detecting a response reaction of a mammal to a silicone, comprising materials, buffers, auxiliary agents, and substances for performing the method according to any of claims 10 to 17. 10
19. A method for monitoring a response reaction of a mammal to a silicone, comprising a) implanting at least one silicone into said mammal, and b) detecting the presence or a change in expression of a silicone-adhering polypeptide according to claim 6 or claim 7 using a method according to any of claims 10 to 17, and, 15 c) optionally, repeating step b).
20. A method for screening substances that interfere with the binding of a silicone-adhering protein and/or polypeptide to a silicone, comprising the steps of a) providing a substance, wherein said substance is suspected to interfere with the 20 adhering properties of a silicone-adhering polypeptide; b) providing a silicone; c) providing a silicone-adhering polypeptide; and; d) analyzing the interfering properties of said substance through analyzing the adhesion of said silicone-adhering polypeptide to said silicone in the presence and 25 absence of said substance, wherein a change in the adhesion of said silicone-adhering polypeptide to said silicone in the presence and absence of said substance is indicative for a substances that interferes with the binding of a silicone-adhering protein and/or polypeptide to a silicone. 30
21. The method according to claim 20, wherein said silicone-adhering polypeptide is selected of the group consisting of a polypeptide according to claim 6 or 7, Myeloid related protein 8, Myeloid related protein 14, HT018, PR02619, a polypeptide identified according to any of claims 1 to 4, Isotype control, IgG-HRP, IgE-HRP, and WO 2007/082757 PCT/EP2007/000442 -58 IGA-HRP, AMBP protein precursor, Plasma-retinol binding protein, Kininogen, Eosinophil peroxidase, Fibroblast growth factor 11, TGF-p, Integrin-p4, T-cell receptor, NADH dehydrogenase, Coagulation factor V, c-spectrin, Monocyte chemotactic protein-2, y-glutamyltransferase, Immunoglobulin G, Immunoglobulin A, 5 Complement C3, Complement C2, Complement Cls, C reactive protein, Alpha 1 microglobulin/bikunin precursor, Von Willebrandt Factor, Fibronectin, Vitronectin, Fibrinogen, Collagen I, Collagen III, Collagen IV, Collagen VII, Procollagen III, Laminin, Matrixmetalloproteinase 2, Apolipoprotein 4, Apolipoprotein Al, Ceruloplasmin, Thyreotyrein, Albumin, Alpha 2-macroglobulin precursor, Haptoglobin .10 1, a and P globin chains, Actin, and HSP 60, Apolipoprotein E3, Complement C2 precursor, Complement C3 precursor, Haemoglobin, Transthyretin or functional variants thereof.
22. A method for detecting adhesion of cells to a silicone, comprising 15 a) providing a sample of serum or wound bed fluid of a mammal containing cells; b) providing a silicone; and c) analyzing the amount or number of cells from said serum or wound bed fluid that adhere to said silicone. 20
23. A substance that interferes with the binding of a silicone-adhering protein and/or polypeptide to a silicone, identified according to a method according to claim 20 or 21.
24. A method for producing a pharmaceutical composition, comprising a method according to a method according to claim 20 or 21, and formulating said substance 25 into a pharmaceutical composition.
25. A pharmaceutical composition comprising a substance according to claim 23 or that is produced according to claim 24. 30
26. A method of treating a mammal suffering from an adverse reaction to an implanted silicone, comprising administering to said mammal an effective amount of the substance according to claim 23 or the pharmaceutical composition according to claim 25. WO 2007/082757 PCT/EP2007/000442 -59.
27. The method according to claim 26, wherein said adverse reaction is a silicosis and/or silicone-related fibrosis.
28. The method according to any of claims I to 4, 10 to 17, 22, and 26 or 27, wherein said 5 mammal is a human.
AU2007207089A 2006-01-18 2007-01-18 Test systems for the analysis of polypeptides and cells adhering to silicones Abandoned AU2007207089A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06001053A EP1811297A1 (en) 2006-01-18 2006-01-18 Test systems for the analysis of polypeptides and cells adhering to silicones
EP06001053.5 2006-01-18
US76042606P 2006-01-20 2006-01-20
US60/760,426 2006-01-20
PCT/EP2007/000442 WO2007082757A2 (en) 2006-01-18 2007-01-18 Test systems for the analysis of polypeptides and cells adhering to silicones

Publications (1)

Publication Number Publication Date
AU2007207089A1 true AU2007207089A1 (en) 2007-07-26

Family

ID=38042562

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007207089A Abandoned AU2007207089A1 (en) 2006-01-18 2007-01-18 Test systems for the analysis of polypeptides and cells adhering to silicones

Country Status (4)

Country Link
JP (1) JP2009524031A (en)
AU (1) AU2007207089A1 (en)
CA (1) CA2636353A1 (en)
WO (1) WO2007082757A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
MX347788B (en) * 2007-02-12 2017-05-12 A1M Pharma Ab Diagnosis and treatment of preeclampsia.
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
WO2009055427A2 (en) 2007-10-22 2009-04-30 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
BR102014004679B1 (en) * 2014-02-27 2021-04-20 Fundação Oswaldo Cruz predictive method for differential diagnosis of meningitis in vitro, use of biomarker proteins, and, kit for differential diagnosis of meningitis to determine whether an individual has bacterial meningitis or viral meningitis
CN104193817B (en) * 2014-09-05 2016-09-14 桂林英美特生物技术有限公司 The purifying process of human retinol-binding protein and the preparation technology of polyclonal antibody thereof
ES2797298T3 (en) 2016-02-10 2020-12-01 Becton Dickinson France Procedure to evaluate the stability of a protein-based formulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834215A (en) * 1994-10-05 1998-11-10 The Administrators Of The Tulane Educational Fund Method for detecting antipolymer antibodies and diagnosing silicone related disease (SRD) fibromyalgia and chronic fatigue syndrome (CFS)

Also Published As

Publication number Publication date
WO2007082757A2 (en) 2007-07-26
WO2007082757A3 (en) 2007-09-20
CA2636353A1 (en) 2007-07-26
JP2009524031A (en) 2009-06-25

Similar Documents

Publication Publication Date Title
AU2007207089A1 (en) Test systems for the analysis of polypeptides and cells adhering to silicones
Munger et al. Interactions between growth factors and integrins: latent forms of transforming growth factor-β are ligands for the integrin αvβ1
US7776361B2 (en) NELL-1 enhanced bone mineralization
Uruno et al. Haematopoietic lineage cell-specific protein 1 (HS1) promotes actin-related protein (Arp) 2/3 complex-mediated actin polymerization
Shimizu et al. Epithelial morphogenesis in hydra requires de novo expression of extracellular matrix components and matrix metalloproteinases
KR101393144B1 (en) Kit and method for detecting urothelial cancer
AU2012219184A1 (en) Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity
Martina et al. Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro
US20110135606A1 (en) Test systems for the analysis of polypeptides and cells adhering to silicones
CA2635906A1 (en) Materials and methods for identifying agents that modulate norrin. norrin mimetics, and agents identified thereby
Nosala et al. Disc-associated proteins mediate the unusual hyperstability of the ventral disc in Giardia lamblia
SHEEHAN et al. Biosynthesis of the MUC2 mucin: evidence for a slow assembly of fully glycosylated units
US20100035360A1 (en) Reagent for detection of autoantibody and kit for diagnosis of autoimmune disease
JP2004500807A (en) Screening method for candidate drugs
Chintala et al. The effect of type III collagen on migration and invasion of human glioblastoma cell lines in vitro
US7354709B2 (en) Collapsin response mediator protein-1
Litwin et al. Gelsolin in human colon adenocarcinoma cells with different metastatic potential
Kanda et al. Pigment epithelium-derived factor inhibits fibroblast-growth-factor-2-induced capillary morphogenesis of endothelial cells through Fyn
EP3378947B1 (en) Use of ed-b protein in diagnosis of tissue hyperplasia
Nakaoka et al. The inhibitory mechanism of gap junctional intercellular communication induced by polyethylene and the restorative effects by surface modification with various proteins
EP2908876B1 (en) Collagen-derived recombinant proteins with von willebrand factor-binding activity
US20240241134A1 (en) Novel biological markers in the diagnosis of endometriosis
CA2374000A1 (en) Use of soluble protein molecules expressed by the pancreas and kidney glomerulus
Alshumaimeri Identification of Protein-Protein Interactors of The Corneal Dystrophy-Causing Protein, SLC4A11
Tu Type XIII collagen: structural and functional characterization of the ectodomain and identification of the binding ligands

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period